

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

|      |    |        |   |
|------|----|--------|---|
| NEWS | 1  |        | Web Page for STN Seminar Schedule - N. America  |
| NEWS | 2  | AUG 10 | Time limit for inactive STN sessions doubles to 40 minutes  |
| NEWS | 3  | AUG 18 | COMPENDEX indexing changed for the Corporate Source (CS) field  |
| NEWS | 4  | AUG 24 | ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  |
| NEWS | 5  | AUG 24 | CA/CAPLUS enhanced with legal status information for U.S. patents   |
| NEWS | 6  | SEP 09 | 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY   |
| NEWS | 7  | SEP 11 | WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus   |
| NEWS | 8  | OCT 21 | Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded                                 |
| NEWS | 9  | OCT 21 | Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models |
| NEWS | 10 | NOV 23 | Addition of SCAN format to selected STN databases   |
| NEWS | 11 | NOV 23 | Annual Reload of IFI Databases  |
| NEWS | 12 | DEC 01 | FRFULL Content and Search Enhancements  |
| NEWS | 13 | DEC 01 | DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets                         |
| NEWS | 14 | DEC 02 | Derwent World Patent Index: Japanese FI-TERM thesaurus added  |
| NEWS | 15 | DEC 02 | PCTGEN enhanced with patent family and legal status display data from INPADOCDB                               |
| NEWS | 16 | DEC 02 | USGENE: Enhanced coverage of bibliographic and sequence information   |
| NEWS | 17 | DEC 21 | New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAPLUS   |
| NEWS | 18 | JAN 12 | Match STN Content and Features to Your Information Needs, Quickly and Conveniently                            |
| NEWS | 19 | JAN 25 | Annual Reload of MEDLINE database   |
| NEWS | 20 | FEB 16 | STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download                                 |
| NEWS | 21 | FEB 16 | Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts                                       |
| NEWS | 22 | FEB 16 | New FASTA Display Formats Added to USGENE and PCTGEN  |
| NEWS | 23 | FEB 16 | INPADOCDB and INPAFAMDB Enriched with New Content and Features  |
| NEWS | 24 | FEB 16 | INSPEC Adding Its Own IPC codes and Author's E-mail Addresses   |

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:21:08 ON 02 MAR 2010

=> file registry

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 0.22             | 0.22          |

FILE 'REGISTRY' ENTERED AT 11:21:22 ON 02 MAR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:    1 MAR 2010    HIGHEST RN 1207596-35-7

DICTIONARY FILE UPDATES:   1 MAR 2010    HIGHEST RN 1207596-35-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s thalidomide

L1                    29 THALIDOMIDE

=> s thalidomide/cn

L2                    1 THALIDOMIDE/CN

=> d l1

L1    ANSWER 1 OF 29    REGISTRY    COPYRIGHT 2010 ACS on STN


RN    222991-42-6    REGISTRY

ED    Entered STN:   14 May 1999

CN    1H-Isoindole-1,3(2H)-dione, 2-(5-hydroxy-2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)

OTHER NAMES:

CN 5'-Hydroxythalidomide  
CN CPS 3  
MF C13 H10 N2 O5  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

9 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 11 1-29

L1 ANSWER 1 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 222991-42-6 REGISTRY  
ED Entered STN: 14 May 1999  
CN 1H-Isoindole-1,3(2H)-dione, 2-(5-hydroxy-2,6-dioxo-3-piperidinyl)- (CA  
INDEX NAME)  
OTHER NAMES:  
CN 5'-Hydroxythalidomide  
CN CPS 3  
MF C13 H10 N2 O5  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

9 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 220460-56-0 REGISTRY  
ED Entered STN: 16 Mar 1999  
CN 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(3-fluoro-2,6-dioxo-3-piperidinyl)-  
(CA INDEX NAME)

OTHER NAMES:

CN  $\alpha$ -Fluoro-4-aminothalidomide  
 CN 1,3-Dioxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)-4-aminoisoindoline  
 MF C13 H10 F N3 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 220460-55-9 REGISTRY  
 ED Entered STN: 16 Mar 1999  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(3-fluoro-2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)

OTHER NAMES:

CN  $\alpha$ -Fluorothalidomide  
 CN 1,3-Dioxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)isoindoline  
 CN 3'-Fluorothalidomide  
 MF C13 H9 F N2 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

23 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 23 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 4 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 193012-06-5 REGISTRY  
 ED Entered STN: 22 Aug 1997  
 CN Benzoic acid, 2-(acetyloxy)-, mixt. with 2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, mixt. contg. (9CI)

OTHER NAMES:

CN Thalidomide-aspirin mixt.  
 MF C13 H10 N2 O4 . C9 H8 O4  
 CI MXS  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 50-78-2  
 CMF C9 H8 O4



CM 2

CRN 50-35-1  
 CMF C13 H10 N2 O4



2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 5 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 167273-70-3 REGISTRY  
 ED Entered STN: 06 Sep 1995  
 CN Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11 $\beta$ )-, mixt. with  
 2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione (9CI) (CA INDEX  
 NAME)

OTHER CA INDEX NAMES:


CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, mixt. contg.  
 (9CI)

OTHER NAMES:

CN Thalidomide-prednisolone mixt.  
 MF C21 H28 O5 . C13 H10 N2 O4  
 CI MXS  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 50-35-1  
 CMF C13 H10 N2 O4




CM 2

CRN 50-24-8

CMF C21 H28 O5

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 6 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN

RN 167273-69-0 REGISTRY

ED Entered STN: 06 Sep 1995

CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy-, mixt. with  
2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione (9CI) (CA INDEX  
NAME)

OTHER CA INDEX NAMES:

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, mixt. contg.  
(9CI)

OTHER NAMES:

CN Thalidomide-prednisone mixt.

MF C21 H26 O5 . C13 H10 N2 O4

CI MXS

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 53-03-2

CMF C21 H26 O5


Absolute stereochemistry.



CM 2

CRN 50-35-1

CMF C13 H10 N2 O4



2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 7 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN

RN 167273-68-9 REGISTRY

ED Entered STN: 06 Sep 1995

CN 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, mixt. with 2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, mixt. contg. (9CI)

OTHER NAMES:

CN Thalidomide-indomethacin mixt.

MF C19 H16 Cl N O4 . C13 H10 N2 O4

CI MXS


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 53-86-1


CMF C19 H16 Cl N O4



CM 2

CRN 50-35-1

CMF C13 H10 N2 O4



2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 8 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN

RN 162662-87-5 REGISTRY

ED Entered STN: 03 May 1995

CN 1H-Isoindole-1,3(2H)-dione, 2-(3-methyl-2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)

OTHER NAMES:

CN (±)-3-Methylthalidomide

CN (RS)-3-Methylthalidomide


CN EM 978

DR 123979-22-6

MF C14 H12 N2 O4

SR CA

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1907 TO DATE)

16 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 9 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN

RN 146090-94-0 REGISTRY




ED Entered STN: 23 Feb 1993  
 CN Benzoic acid, 4-(4-morpholinylmethyl)-,  
 [3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-2,6-dioxo-1-piperidinyl]methyl  
 ester, hydrochloride (1:1) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzoic acid, 4-(4-morpholinylmethyl)-,  
 [3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-2,6-dioxo-1-piperidinyl]methyl  
 ester, monohydrochloride (9CI)  
 OTHER NAMES:  
 CN N-[[ (Morpholinomethyl)benzoyl]oxy]methylthalidomide hydrochloride  
 MF C26 H25 N3 O7 . Cl H  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT  
 CRN (756447-75-3)

PAGE 1-A




PAGE 2-A



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


RN 145945-21-7 REGISTRY  
 ED Entered STN: 16 Feb 1993  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[1-(hydroxymethyl)-2,6-dioxo-3-piperidinyl]-  
 (CA INDEX NAME)  
 OTHER NAMES:  
 CN 2-[1-(Hydroxymethyl)-2,6-dioxopiperidin-3-yl]isoindoline-1,3-dione  
 CN CPS 11  
 CN N-(Hydroxymethyl)thalidomide  
 MF C14 H12 N2 O5  
 SR CA  
 LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

14 REFERENCES IN FILE CA (1907 TO DATE)  
 14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 11 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 127869-71-0 REGISTRY  
 ED Entered STN: 29 Jun 1990  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(1,3-dimethyl-2,6-dioxo-3-piperidinyl)- (CA  
 INDEX NAME)  
 OTHER NAMES:  
 CN 1,3-Dimethylthalidomide  
 DR 123979-25-9  
 MF C15 H14 N2 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 12 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 124095-10-9 REGISTRY  
 ED Entered STN: 08 Dec 1989  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[(3R)-2,6-dioxo-3-propyl-3-piperidinyl]-  
 (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-propyl-3-piperidinyl)-, (R)-

OTHER NAMES:

CN (R)-3-Propylthalidomide


FS STEREOSEARCH

MF C16 H16 N2 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 13 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN

RN 124095-09-6 REGISTRY

ED Entered STN: 08 Dec 1989

CN 1H-Isoindole-1,3(2H)-dione, 2-[(3S)-2,6-dioxo-3-propyl-3-piperidinyl]-  
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-propyl-3-piperidinyl)-, (S)-

OTHER NAMES:

CN (S)-3-Propylthalidomide


FS STEREOSEARCH

MF C16 H16 N2 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


5 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 14 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN

RN 124095-08-5 REGISTRY  
 ED Entered STN: 08 Dec 1989  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[(3R)-3-ethyl-2,6-dioxo-3-piperidiny]- (CA  
 INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(3-ethyl-2,6-dioxo-3-piperidiny)-, (R)-  
 OTHER NAMES:  
 CN (R)-3-Ethylthalidomide  
 FS STEREOSEARCH  
 MF C15 H14 N2 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry. Rotation (-).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 15 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 124095-07-4 REGISTRY  
 ED Entered STN: 08 Dec 1989  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[(3S)-3-ethyl-2,6-dioxo-3-piperidiny]- (CA  
 INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(3-ethyl-2,6-dioxo-3-piperidiny)-, (S)-  
 OTHER NAMES:  
 CN (S)-3-Ethylthalidomide  
 FS STEREOSEARCH  
 MF C15 H14 N2 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT


Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 16 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 123979-24-8 REGISTRY  
 ED Entered STN: 01 Dec 1989  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-propyl-3-piperidinyl)- (CA  
 INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-propyl-3-piperidinyl)-, (±)-  
 OTHER NAMES:  
 CN (±)-3-Propylthalidomide  
 CN (RS)-3-Propylthalidomide  
 MF C16 H16 N2 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 17 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 123979-23-7 REGISTRY  
 ED Entered STN: 01 Dec 1989  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(3-ethyl-2,6-dioxo-3-piperidinyl)- (CA  
 INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(3-ethyl-2,6-dioxo-3-piperidinyl)-, (±)-  
 OTHER NAMES:  
 CN (±)-3-Ethylthalidomide  
 CN (RS)-3-Ethylthalidomide  
 MF C15 H14 N2 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 18 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN

RN 108816-41-7 REGISTRY  
 ED Entered STN: 28 Jun 1987  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[(3R)-3-methyl-2,6-dioxo-3-piperidinyl]-  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(3-methyl-2,6-dioxo-3-piperidinyl)-, (R)-  
 OTHER NAMES:  
 CN (R)-3-Methylthalidomide  
 FS STEREOSEARCH  
 MF C14 H12 N2 O4  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER  
 (\*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1907 TO DATE)  
 16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 19 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 108816-40-6 REGISTRY  
 ED Entered STN: 28 Jun 1987  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[(3S)-3-methyl-2,6-dioxo-3-piperidinyl]-  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(3-methyl-2,6-dioxo-3-piperidinyl)-, (S)-  
 OTHER NAMES:  
 CN (S)-3-Methylthalidomide  
 FS STEREOSEARCH  
 DR 127869-70-9  
 MF C14 H12 N2 O4  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER  
 (\*File contains numerically searchable property data)


Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1907 TO DATE)  
16 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 20 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 64567-60-8 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidiny1)-5-hydroxy- (CA  
INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Phthalimide, N-(2,6-dioxo-3-piperidyl)-4-hydroxy- (7CI)  
OTHER NAMES:  
CN 5-Hydroxythalidomide  
MF C13 H10 N2 O5  
LC STN Files: ANABSTR, BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

27 REFERENCES IN FILE CA (1907 TO DATE)  
27 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 21 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 31804-66-7 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5H-Pyrrolo[3,4-b]pyridine-5,7(6H)-dione, 6-(2,6-dioxo-3-piperidiny1)- (CA  
INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 2,3-Pyridinedicarboximide, N-(2,6-dioxo-3-piperidyl)- (8CI)  
OTHER NAMES:  
CN 3-Azathalidomide  
MF C12 H9 N3 O4  
LC STN Files: BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, EMBASE,  
IFICDB, IFIPAT, IFIUDB, RTECS\*, TOXCENTER, USPATFULL, USPATOLD  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1907 TO DATE)  
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 22 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 19171-18-7 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-nitro- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Phthalimide, N-(2,6-dioxo-3-piperidyl)-3-nitro- (7CI, 8CI)  
 OTHER NAMES:  
 CN 4-Nitrothalidomide  
 MF C13 H9 N3 O6  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, RTECS\*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

13 REFERENCES IN FILE CA (1907 TO DATE)  
 13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 23 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 14578-56-4 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2,6-dioxo-1-(1-piperidinylmethyl)-3-piperidinyl]- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Phthalimide, N-[2,6-dioxo-1-(piperidinomethyl)-3-piperidyl]- (8CI)  
 OTHER NAMES:  
 CN 1-Piperidinomethylthalidomide  
 MF C19 H21 N3 O4  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATOLD  
 (\*File contains numerically searchable property data)






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 24 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 10329-96-1 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 1H-Isoindole-1,3(2H)-dione, 2-[1-(4-morpholinylmethyl)-2,6-dioxo-4-piperidinyl]- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Phthalimide, N-[1-(morpholinomethyl)-2,6-dioxo-4-piperidyl]- (8CI)  
OTHER NAMES:  
CN 1-(Morpholinomethyl)-4-phthalimidopiperidine-2,6-dione  
CN CG 603  
CN Morpholino- $\beta$ -thalidomide  
CN N-[1-(Morpholinomethyl)-2,6-dioxo-4-piperidyl]phthalimide  
MF C18 H19 N3 O5  
LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, RTECS\*, TOXCENTER, USPATOLD  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1907 TO DATE)  
16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 25 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 10329-95-0 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 1H-Isoindole-1,3(2H)-dione, 2-[1-(4-morpholinylmethyl)-2,6-dioxo-3-piperidinyl]- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Phthalimide, N-[1-(morpholinomethyl)-2,6-dioxo-3-piperidyl]- (8CI)  
OTHER NAMES:  
CN 1-Morpholinomethyl-3-phthalimidopiperidine-2,6-dione  
CN 1-Morpholinomethylthalidomide  
CN CG 601  
CN Morpholinothalidomide  
CN N-[2,6-Dioxo-1-(morpholinomethyl)-3-piperidyl]phthalimide  
DR 158903-01-6  
MF C18 H19 N3 O5  
LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, RTECS\*, TOXCENTER, USPAT2, USPATFULL, USPATOLD  
(\*File contains numerically searchable property data)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

18 REFERENCES IN FILE CA (1907 TO DATE)  
18 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 26 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 2614-06-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 1H-Isoindole-1,3(2H)-dione, 2-[(3R)-2,6-dioxo-3-piperidinyl]- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, (R)-  
CN Phthalimide, N-(2,6-dioxo-3-piperidyl)-, D-(+)- (8CI)  
OTHER NAMES:  
CN (+)-(R)-Thalidomide  
CN (+)-Thalidomide  
CN (R)-(+)-Thalidomide  
CN (R)-Thalidomide  
CN NSC 91729  
CN R-(D)-Thalidomide  
FS STEREOSEARCH  
MF C13 H10 N2 O4  
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CIN, CSCHEM, IPA, PROMT, RTECS\*, TOXCENTER, USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

114 REFERENCES IN FILE CA (1907 TO DATE)  
114 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 27 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 841-67-8 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 1H-Isoindole-1,3(2H)-dione, 2-[(3S)-2,6-dioxo-3-piperidinyl]- (CA INDEX NAME)  
OTHER CA INDEX NAMES:

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidiny)-, (S)-  
 CN Phthalimide, N-(2,6-dioxo-3-piperidyl)-, L-(-)- (8CI)  
 OTHER NAMES:  
 CN (-)-Thalidomide  
 CN (S)-(-)-Thalidomide  
 CN (S)-Thalidomide  
 CN NSC 91730  
 CN S-(L)-Thalidomide  
 FS STEREOSEARCH  
 MF C13 H10 N2 O4  
 LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT,  
 CHEMCATS, CSCHEM, IFICDB, IFIPAT, IFIUDB, IPA, PROMT, RTECS\*, TOXCENTER,  
 USPATFULL  
 (\*File contains numerically searchable property data)


Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

127 REFERENCES IN FILE CA (1907 TO DATE)  
 127 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 28 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
 RN 303-31-1 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-4-piperidiny)- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Phthalimide, N-(2,6-dioxo-4-piperidyl)- (7CI, 8CI)  
 OTHER NAMES:  
 CN  $\beta$ -Thalidomide  
 CN CG 809  
 CN E 350  
 CN E 350 (pharmaceutical)  
 MF C13 H10 N2 O4  
 LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, DDFU, DRUGU, RTECS\*,  
 TOXCENTER, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

15 REFERENCES IN FILE CA (1907 TO DATE)  
15 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 29 OF 29 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 50-35-1 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Phthalimide, N-(2,6-dioxo-3-piperidyl)- (6CI, 7CI, 8CI)  
OTHER NAMES:  
CN (+)-Thalidomide  
CN  $\alpha$ -(N-Phthalimido)glutarimide  
CN  $\alpha$ -N-Phthalylglutaramide  
CN  $\alpha$ -Phthalimidoglutaramide  
CN 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline  
CN 3-Phthalimidoglutaramide  
CN Celgene  
CN Contergan  
CN Distaval  
CN K 17  
CN Kevadon  
CN Myrin  
CN N-(2,6-Dioxo-3-piperidyl)phthalimide  
CN N-Phthaloylglutamimide  
CN Neurosedyn  
CN NSC 527179  
CN NSC 66847  
CN Pantosediv  
CN Pharmion  
CN Quetimid  
CN Sauramide  
CN Sedalis  
CN Sedoval  
CN Softenil  
CN Softenon  
CN Suaramide  
CN Talimol  
CN Talinol  
CN Thalidomide  
CN Thalomid  
DR 14088-68-7, 731-40-8  
MF C13 H10 N2 O4  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*,  
BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,  
CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB\*, IMSDRUGNEWS, IMSPATENTS,  
IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK\*, MSDS-OHS, PATDPASPC, PIRA,  
PROMT, PROUSDDR, PS, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, USAN,  
USPAT2, USPATFULL, USPATOLD  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3511 REFERENCES IN FILE CA (1907 TO DATE)  
 208 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 3525 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 50-35-1/rn or 841-67-8/rn or 2614-06-4/rn

1 50-35-1/RN

1 841-67-8/RN

1 2614-06-4/RN

L3 3 50-35-1/RN OR 841-67-8/RN OR 2614-06-4/RN

=> file caplus s l3

'S' IS AN AMBIGUOUS FILE OR CLUSTER NAME

|            |   |
|------------|---|
| SAFETY     | - Occupational Health and Safety Cluster                |
| SESSION    | - Current files with L-numbers Cluster                  |
| STNLIS     | - LIS system files cluster                              |
| STRUCTURE  | - Structure Searching Cluster                           |
| SUPPLIERS  | - Product Directories and Suppliers Cluster             |
| SCISEARCH  | - ISI Science Citation Index from 1974 - present        |
| SOFIS      | - Social Science Research Information System 1997-2006  |
| SOLIDSTATE | - Solid State and Superconductivity Abstracts from 1981 |
| SOLIS      | - German literature in social sciences 1945-present     |
| SPECINFO   | - Spectral Database Information System                  |
| STNGUIDE   | - Descriptive information about STN databases           |
| STNMAIL    | - STN Electronic Mail Service                           |
| SYNTHLINE  | - Synthline Drug Synthesis Database 1984-present        |

ENTER FILE OR CLUSTER NAME (IGNORE):caplus

'L3' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):stn guide

'STN' IS AN AMBIGUOUS FILE OR CLUSTER NAME

|          |   |
|----------|---|
| STNLIS   | - LIS system files cluster                    |
| STNGUIDE | - Descriptive information about STN databases |
| STNMAIL  | - STN Electronic Mail Service                 |

ENTER FILE OR CLUSTER NAME (IGNORE):stnguide

MULTIFILE PROCESSING IS NOT ALLOWED IN FILE 'STNGUIDE'

The file entered is not valid in multifile processing. Enter "HELP DUFILES" to see a list of the valid files.

ENTER A FILE NAME OR (IGNORE):ingnore

'INGNORE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

'GUIDE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files

that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):

ENTER A FILE NAME OR (IGNORE):safety

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

76.45

76.67

FILE 'CAPLUS' ENTERED AT 11:24:36 ON 02 MAR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE '1MOBILITY' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (C) 2010 Society of Automotive Engineers, Inc.

FILE '2MOBILITY' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (C) 2010 Society of Automotive Engineers, Inc.

FILE 'CEABA-VTB' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (c) 2010 DECHEMA eV

FILE 'CHEMLIST' ENTERED AT 11:24:36 ON 02 MAR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

FILE 'CHEMSAFE' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (C) 2010 DECHEMA / Physikalisch-Technische Bundesanstalt (PTB) / Bundesanstalt fuer Materialforschung und -pruefung (BAM)

FILE 'CIN' ENTERED AT 11:24:36 ON 02 MAR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

FILE 'CSNB' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (c) 2010 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'HEALSAFE' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (C) 2010 Cambridge Scientific Abstracts (CSA)

FILE 'HSDB' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (C) 2010 NATIONAL LIBRARY OF MEDICINE

FILE 'INSPEC' ENTERED AT 11:24:36 ON 02 MAR 2010

Compiled and produced by the IET in association WITH FIZ KARLSRUHE

COPYRIGHT 2010 (c) THE INSTITUTION OF ENGINEERING AND TECHNOLOGY (IET)

FILE 'ITRD' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (C) 2010 Organisation for Economic Co-operation and Development (OECD), Road Transport Research, Paris

FILE 'MSDS-CCOHS' ENTERED AT 11:24:36 ON 02 MAR 2010

Copyright Notice: Permission to copy is not required for this file

FILE 'MSDS-OHS' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (C) 2010 ChemADVISOR, Inc.

FILE 'NAPRALERT' ENTERED AT 11:24:36 ON 02 MAR 2010

COPYRIGHT (C) 2010 Board of Trustees of the University of Illinois,  
University of Illinois at Chicago.

FILE 'PASCAL' ENTERED AT 11:24:36 ON 02 MAR 2010  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2010 INIST-CNRS. All rights reserved.

FILE 'POLLUAB' ENTERED AT 11:24:36 ON 02 MAR 2010  
COPYRIGHT (C) 2010 Cambridge Scientific Abstracts (CSA)

FILE 'PROMT' ENTERED AT 11:24:36 ON 02 MAR 2010  
COPYRIGHT (C) 2010 Gale Group. All rights reserved.

FILE 'RTECS' ENTERED AT 11:24:36 ON 02 MAR 2010  
PORTIONS COPYRIGHT (C) 2010 U.S. GOVERNMENT  
RTECS(R) is a United States trademark owned and licensed under  
authority of the U.S. Government, by and through Symyx Software, Inc.

FILE 'SCISEARCH' ENTERED AT 11:24:36 ON 02 MAR 2010  
Copyright (c) 2010 The Thomson Corporation

|                      |            |         |
|----------------------|------------|---------|
| => file caplus       |            |         |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL   |
|                      | ENTRY      | SESSION |
| FULL ESTIMATED COST  | 25.45      | 102.12  |

FILE 'CAPLUS' ENTERED AT 11:24:40 ON 02 MAR 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Mar 2010 VOL 152 ISS 10  
FILE LAST UPDATED: 1 Mar 2010 (20100301/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
L4 3569 L3

```
=> s 14 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm? or ?leukemia? or
?myeloma?)
    498023 ?CANCER?
    776504 ?TUMOR?
    6941 ?TUMOUR?
    6941 ?TUMOUR?
    776905 ?TUMOR?
        (?TUMOR? OR ?TUMOUR?)
    6941 ?TUMOUR?
    776504 ?TUMOR?
    776504 ?TUMOR?
    776905 ?TUMOUR?
        (?TUMOUR? OR ?TUMOR?)
    601577 ?NEOPLASM?
    133484 ?LEUKEMIA?
    1814 ?LEUKAEMIA?
    1814 ?LEUKAEMIA?
    133534 ?LEUKEMIA?
        (?LEUKEMIA? OR ?LEUKAEMIA?)
    25082 ?MYELOMA?
L5      2230 L4 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM? OR ?LEUKEM
        IA? OR ?MYELOMA?)
```

```
=> s 15 and ad<19930301
    2653054 AD<19930301
        (AD<19930301)
L6      2 L5 AND AD<19930301

=> dup rem 16
PROCESSING COMPLETED FOR L6
L7      2 DUP REM L6 (0 DUPLICATES REMOVED)
```

```
=> d 17 1-2 ibib abs
```

```
L7      ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:      2004:41116  CAPLUS
DOCUMENT NUMBER:      140:105248
TITLE:      Synthesis and antiproliferative effects of
              1 $\alpha$ ,24(S)-dihydroxyvitamin D2, and use with other
              agents
INVENTOR(S):      Bishop, Charles W.; Knutson, Joyce C.; Strugnelli,
                  Stephen; Mazess, Richard B.
PATENT ASSIGNEE(S):      Bone Care International, Inc., USA
SOURCE:      U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S.
              Pat. Appl. 2002 32,179.
              CODEN: USXXCO
DOCUMENT TYPE:      Patent
LANGUAGE:      English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:
```

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE         |
|---|------|----------|-----------------|--------------|
| -----   | ---- | -----    | -----           | -----        |
| US 20040009958  | A1   | 20040115 | US 2003-390953  | 20030318     |
| WO 9212165  | A1   | 19920723 | WO 1992-US313   | 19920107 <-- |
| W: AU, BR, CA, FI, HU, JP, KP, KR, NO, PL, RU, US             |      |          |                 |              |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE    |      |          |                 |              |
| EP 914825   | A2   | 19990512 | EP 1998-110802  | 19920107 <-- |
| EP 914825   | A3   | 19990519 |                 |              |
| EP 914825   | B1   | 20030521 |                 |              |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC |      |          |                 |              |



|                        |  |          |                  |             |
|------------------------|--|----------|------------------|-------------|
| US 5786348             | A  | 19980728 | US 1995-477930   | 19950607    |
| US 5789397             | A  | 19980804 | US 1995-485184   | 19950607    |
| US 6166000             | A  | 20001226 | US 1995-472499   | 19950607    |
| US 6143910             | A  | 20001107 | US 1998-211984   | 19981214    |
| US 6251883             | B1   | 20010626 | US 1998-211991   | 19981214    |
| US 20020032179         | A1   | 20020314 | US 2001-891963   | 20010626    |
| US 6538037             | B2   | 20030325 |                  |             |
| CA 2451039             | A1   | 20030109 | CA 2002-2451039  | 20020626    |
| WO 2003002110          | A1   | 20030109 | WO 2002-US20317  | 20020626    |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW                                 |          |                  |             |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                  |             |
| AU 2002315463          | A1   | 20030303 | AU 2002-315463   | 20020626    |
| AU 2002315463          | B2   | 20070531 |                  |             |
| EP 1408939             | A1   | 20040421 | EP 2002-742318   | 20020626    |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR   |          |                  |             |
| CN 1520288             | A  | 20040811 | CN 2002-812836   | 20020626    |
| JP 2004535441          | T  | 20041125 | JP 2003-508349   | 20020626    |
| MX 2003011306          | A  | 20040319 | MX 2003-11306    | 20031208    |
| AU 2004222310          | A1   | 20040930 | AU 2004-222310   | 20040316    |
| CA 2517125             | A1   | 20040930 | CA 2004-2517125  | 20040316    |
| WO 2004082631          | A2   | 20040930 | WO 2004-US8136   | 20040316    |
| WO 2004082631          | A3   | 20051229 |                  |             |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                  |             |
| RW:                    | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                  |             |
| EP 1617810             | A2   | 20060125 | EP 2004-749390   | 20040316    |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK   |          |                  |             |
| BR 2004008468          | A  | 20060404 | BR 2004-8468     | 20040316    |
| CN 1774242             | A  | 20060517 | CN 2004-80007470 | 20040316    |
| JP 2006520791          | T  | 20060914 | JP 2006-507271   | 20040316    |
| PRIORITY APPLN. INFO.: |  |          | US 1991-637867   | B2 19910108 |
|                        |  |          | WO 1992-US313    | A2 19920107 |
|                        |  |          | US 1992-940246   | B1 19920828 |
|                        |  |          | US 1994-275641   | B1 19940714 |
|                        |  |          | US 1995-515801   | B2 19950816 |
|                        |  |          | US 1998-211991   | A2 19981214 |
|                        |  |          | US 2001-891963   | A2 20010626 |
|                        |  |          | EP 1992-904947   | A3 19920107 |
|                        |  |          | WO 2002-US20317  | W 20020626  |
|                        |  |          | US 2003-390953   | A 20030318  |
|                        |  |          | WO 2004-US8136   | A 20040316  |

AB The invention discloses the hormonally active, natural metabolite 1 $\alpha$ ,24(S)-dihydroxyvitamin D2 and a method of preparing this metabolite and the nonbiol. epimer 1 $\alpha$ ,24(R)-dihydroxyvitamin D2. The invention also relates to a pharmaceutical composition including a pharmaceutically

effective amount of 1 $\alpha$ ,24(S)-dihydroxyvitamin D<sub>2</sub>, to a method of controlling abnormal calcium metabolism by administering a pharmaceutically effective amount of the compound, and to a method of treating hyperproliferative diseases by administering the compound. The method also includes the co-administration of cytotoxic agents with the 1 $\alpha$ ,24(S)-dihydroxyvitamin D<sub>2</sub>.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1992:626313 CAPLUS

DOCUMENT NUMBER: 117:226313

ORIGINAL REFERENCE NO.: 117:38893a,38896a

TITLE: Controlling abnormal concentration of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) in human tissues with phthalimido dioxopiperidines and related compounds

INVENTOR(S): Kaplan, Gilla; Sampaio, Elisabeth P.

PATENT ASSIGNEE(S): Rockefeller University, USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE         |
|--|------|----------|-----------------|--------------|
| WO 9214455   | A1   | 19920903 | WO 1992-US1207  | 19920214 <-- |
| W: AU, CA, JP  |      |          |                 |              |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE |      |          |                 |              |
| AU 9215314   | A    | 19920915 | AU 1992-15314   | 19920214 <-- |
| US 5385901   | A    | 19950131 | US 1992-955936  | 19921002 <-- |
| PRIORITY APPLN. INFO.:                                     |      |          | US 1991-655087  | A 19910214   |
|  |      |          | US 1992-834588  | A 19920212   |
|  |      |          | WO 1992-US1207  | A 19920214   |

GI



AB The dioxopiperidine derivs. I (R = H, alkyl, Ph, benzyl; R<sub>1</sub> = phthalamide or succinimido radical) and II (X = CH<sub>2</sub>, CO; R<sub>2</sub> = H, Et, Ph, benzyl, CH<sub>2</sub>CH:CH<sub>2</sub>, Q) and II hydrolysis products, are drugs for treatment of the debilitating effects of toxic TNF- $\alpha$  levels in humans, such as in septic shock, cachexia and human immunodeficiency virus infection. Thalidomide (2 ng to 10  $\mu$ g/mL) decreased the tuberculin-stimulated production of TNF- $\alpha$  in human monocytes in vitro. The preparation of thalidomide and 3-phthalimido-2,6-dioxo-1-ethylpiperidine are given.

OS.CITING REF COUNT: 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 11:21:08 ON 02 MAR 2010)

FILE 'REGISTRY' ENTERED AT 11:21:22 ON 02 MAR 2010

L1 29 S THALIDOMIDE  
L2 1 S THALIDOMIDE/CN  
L3 3 S 50-35-1/RN OR 841-67-8/RN OR 2614-06-4/RN

FILE 'CAPLUS, 1MOBILITY, 2MOBILITY, CEABA-VTB, CHEMLIST, CHEMSAFE, CIN, CSNB, HEALSAFE, HSDB, INSPEC, ITRD, MSDS-CCOHS, MSDS-OHS, NAPRALERT, PASCAL, POLLUAB, PROMT, RTECS, SCISEARCH' ENTERED AT 11:24:36 ON 02 MAR 2010

FILE 'CAPLUS' ENTERED AT 11:24:40 ON 02 MAR 2010

L4 3569 S L3  
L5 2230 S L4 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM? OR ?LEU  
L6 2 S L5 AND AD<19930301  
L7 2 DUP REM L6 (0 DUPLICATES REMOVED)

=> file medline embase biosis

| COST IN U.S. DOLLARS                       | SINCE FILE<br>ENTRY | TOTAL<br>SESSION |
|--|---------------------|------------------|
| FULL ESTIMATED COST                        | 24.37               | 126.49           |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE<br>ENTRY | TOTAL<br>SESSION |
| CA SUBSCRIBER PRICE                        | -1.70               | -1.70            |

FILE 'MEDLINE' ENTERED AT 11:27:01 ON 02 MAR 2010

FILE 'EMBASE' ENTERED AT 11:27:01 ON 02 MAR 2010  
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:27:01 ON 02 MAR 2010  
Copyright (c) 2010 The Thomson Corporation

=> s l3<chem> or l3

SmartSELECT INITIATED

New TRANSFER and ANALYZE Commands Now Available  
See HELP TRANSFER and HELP ANALYZE for Details

| COST IN U.S. DOLLARS                       | SINCE FILE<br>ENTRY | TOTAL<br>SESSION |
|--|---------------------|------------------|
| FULL ESTIMATED COST                        | 3.33                | 129.82           |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE<br>ENTRY | TOTAL<br>SESSION |
| CA SUBSCRIBER PRICE                        | 0.00                | -1.70            |

FILE 'REGISTRY' ENTERED AT 11:27:11 ON 02 MAR 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

SET SMARTSELECT ON  
SET COMMAND COMPLETED

SEL L3 1- CHEM

L8 SEL L3 1- CHEM : 46 TERMS

SET SMARTSELECT OFF  
SET COMMAND COMPLETED

| COST IN U.S. DOLLARS                       | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST                        | 15.49            | 145.31        |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE                        | 0.00             | -1.70         |

FILE 'MEDLINE' ENTERED AT 11:27:11 ON 02 MAR 2010

FILE 'EMBASE' ENTERED AT 11:27:11 ON 02 MAR 2010  
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:27:11 ON 02 MAR 2010  
Copyright (c) 2010 The Thomson Corporation

S L8 OR L3

L10 24609 L9 OR L3

=> s l10 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm? or ?leukemia? or ?myeloma?)

L11 13424 L10 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM? OR ?LEUKEMIA? OR ?MYELOMA?)

=> s l11 and pd<19930301

1 FILES SEARCHED...

L12 235 L11 AND PD<19930301

=> dup rem l12

PROCESSING COMPLETED FOR L12

L13 180 DUP REM L12 (55 DUPLICATES REMOVED)

=> d l13 1-25 ibib abs

L13 ANSWER 1 OF 180 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1994:86840 BIOSIS

DOCUMENT NUMBER: PREV199497099840

TITLE: Chemical teratogenesis.

AUTHOR(S): Juchau, Mont R.

CORPORATE SOURCE: Dep. Pharmacol., Sch. Med. SJ-30, Univ. Wash., Seattle, WA 98195, USA

SOURCE: Jucker, E. [Editor]. Prog. Drug Res., (1993) pp.

9-50. Progress in Drug Research.

Publisher: Birkhaeuser Verlag, P. O. Box 133, CH-4010

Basel, Switzerland; Birkhaeuser Boston, Inc., 175 Fifth

Avenue, New York, New York 10010, USA. Series: Progress in Drug Research.

CODEN: FAZMAE. ISSN: 0071-786X. ISBN: 3-7643-2925-4, 0-8176-2925-4.

DOCUMENT TYPE: Book

Book; (Book Chapter)

General Review; (Literature Review)

LANGUAGE: English

ENTRY DATE: Entered STN: 5 Mar 1994  
Last Updated on STN: 5 Mar 1994

L13 ANSWER 2 OF 180 MEDLINE on STN DUPLICATE 1  
ACCESSION NUMBER: 1993317606 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8327469  
TITLE: Thalidomide inhibits the replication of human  
immunodeficiency virus type 1.  
AUTHOR: Makonkawkeyoon S; Limson-Pobre R N; Moreira A L; Schauf V;  
Kaplan G  
CORPORATE SOURCE: Rockefeller University, New York, NY 10021.  
CONTRACT NUMBER: AI-22616 (United States NIAID NIH HHS)  
AI-24775 (United States NIAID NIH HHS)  
SOURCE: Proceedings of the National Academy of Sciences of the  
United States of America, (1993 Jul 1) Vol. 90,  
No. 13, pp. 5974-8.  
Journal code: 7505876. ISSN: 0027-8424. L-ISSN: 0027-8424.  
Report No.: NLM-PMC46849.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 199308  
ENTRY DATE: Entered STN: 20 Aug 1993  
Last Updated on STN: 3 Feb 1997  
Entered Medline: 6 Aug 1993

AB Thalidomide, a selective inhibitor of tumor necrosis  
factor alpha (TNF-alpha) synthesis, suppresses the activation of latent  
human immunodeficiency virus type 1 (HIV-1) in a monocytoid (U1) line.  
The inhibition is dose dependent and occurs after exposure of the cells to  
recombinant TNF-alpha, phorbol myristate acetate, lipopolysaccharide, and  
other cytokine combinations. Associated with HIV-1 inhibition is a  
reduction in agonist-induced TNF-alpha protein and mRNA production.  
Thalidomide inhibition of virus replication in the phorbol  
myristate acetate- and recombinant TNF-alpha-stimulated T-cell line ACH-2  
is not observed. The presence of thalidomide also inhibits the  
activation of virus in the peripheral blood mononuclear cells of 16 out of  
17 patients with advanced HIV-1 infection and AIDS. These results suggest  
the use of thalidomide in a clinical setting to inhibit both  
virus replication and the TNF-alpha-induced systemic toxicity of HIV-1 and  
opportunistic infections.

L13 ANSWER 3 OF 180 MEDLINE on STN DUPLICATE 2  
ACCESSION NUMBER: 1993267219 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8496685  
TITLE: Thalidomide exerts its inhibitory action on  
tumor necrosis factor alpha by enhancing mRNA  
degradation.  
AUTHOR: Moreira A L; Sampaio E P; Zmuidzinas A; Frindt P; Smith K  
A; Kaplan G  
CORPORATE SOURCE: Laboratory of Cellular Physiology and Immunology,  
Rockefeller University, New York, New York 10021.  
CONTRACT NUMBER: AI-22616 (United States NIAID NIH HHS)  
AI-33124 (United States NIAID NIH HHS)  
SOURCE: The Journal of experimental medicine, (1993 Jun 1)  
Vol. 177, No. 6, pp. 1675-80.  
Journal code: 2985109R. ISSN: 0022-1007. L-ISSN: 0022-1007.  
Report No.: NLM-PMC2191046.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

(RESEARCH SUPPORT, NON-U.S. GOV'T)  
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 199306  
ENTRY DATE: Entered STN: 2 Jul 1993  
Last Updated on STN: 2 Jul 1993  
Entered Medline: 21 Jun 1993

AB We have examined the mechanism of thalidomide inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha) production and found that the drug enhances the degradation of TNF-alpha mRNA. Thus, the half-life of the molecule was reduced from approximately 30 to approximately 17 min in the presence of 50 micrograms/ml of thalidomide. Inhibition of TNF-alpha production was selective, as other LPS-induced monocyte cytokines were unaffected. Pentoxifylline and dexamethasone, two other inhibitors of TNF-alpha production, are known to exert their effects by means of different mechanisms, suggesting that the three agents inhibit TNF-alpha synthesis at distinct points of the cytokine biosynthetic pathway. These observations provide an explanation for the synergistic effects of these drugs. The selective inhibition of TNF-alpha production makes thalidomide an ideal candidate for the treatment of inflammatory conditions where TNF-alpha-induced toxicities are observed and where immunity must remain intact.

L13 ANSWER 4 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993296796 EMBASE  
TITLE: Bone marrow transplantation and cataract development.  
AUTHOR: Dunn, J.P., Dr. (correspondence); Jabs, D.A.; Wingard, J.; Enger, C.; Vogelsang, G.; Santos, G.  
CORPORATE SOURCE: 550 N Broadway, Baltimore, MD 21205, United States.  
SOURCE: Archives of Ophthalmology, (1993) Vol. 111, No. 10, pp. 1367-1373.  
ISSN: 0003-9950 CODEN: AROPAW  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 012 Ophthalmology  
016 Cancer  
025 Hematology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 14 Nov 1993  
Last Updated on STN: 14 Nov 1993

AB Objectives: To evaluate risk factors for the development of posterior subcapsular cataract following bone marrow transplantation (BMT) and the results of patients undergoing cataract extraction. Design: Retrospective case-control study. Setting: Tertiary referral center. Patients: Three hundred sixty-six patients (59% male, 41% female) undergoing BMT at one institution who survived for at least 1 month and underwent full ophthalmologic examination. Risk factors were then compared between patients who developed posterior subcapsular cataract and those who did not. Intervention: Cataract surgery in six eyes of four patients. Main Outcome Measure: Formation of posterior subcapsular cataract. Data were obtained on all patients for type of BMT, pretransplantation regimen, underlying malignancy, demographic background, complications of BMT, and medications. Results: Forty (10.9%) of 366 patients developed posterior subcapsular cataract. By univariate analysis, cataract formation was associated with total body irradiation, chronic graft-vs-host disease, the use of allogeneic bone marrow, and the total dose and duration of corticosteroid therapy. Multivariate analysis revealed that the total

dose and duration of corticosteroid therapy were the most important risk factors, while total body irradiation was not a statistically significant risk factor. Cataract surgery was performed in six eyes of four patients, all of whom developed visual acuities of 20/40 or better. Conclusion: Posterior subcapsular cataract following BMT is uncommon and rarely requires surgery. Total dose and duration of corticosteroid therapy are the most important risk factors for development of cataract, but total body irradiation is not a statistically significant risk factor.

L13 ANSWER 5 OF 180 MEDLINE on STN DUPLICATE 3  
 ACCESSION NUMBER: 1994080792 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 8258255  
 TITLE: Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.  
 AUTHOR: Schwinghammer T L; Bloom E J  
 CORPORATE SOURCE: Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, PA 15261.  
 SOURCE: Clinical pharmacy, (1993 Oct) Vol. 12, No. 10, pp. 736-61. Ref: 218  
 Journal code: 8207437. ISSN: 0278-2677. L-ISSN: 0278-2677.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199401  
 ENTRY DATE: Entered STN: 3 Feb 1994  
 Last Updated on STN: 3 Feb 1994  
 Entered Medline: 19 Jan 1994

AB The immunology, pathophysiology, incidence, clinical manifestations, grading, and prevention of acute graft-versus-host disease (GVHD) are reviewed. GVHD occurs after allogeneic marrow transplantation when immunologically competent T lymphocytes in the donor marrow identify the host's antigens as foreign and attempt to reject host tissues. Acute GVHD occurs within three months after marrow transplantation and may affect the skin, gastrointestinal tract, liver, and immune system. Even with prophylactic immunosuppression, acute GVHD occurs in 20% to 80% of patients. Moderate to severe GVHD (grades II-IV) is a major cause of morbidity and mortality after allogeneic bone marrow transplantation. Conventional GVHD prophylaxis consists of immunosuppressives such as corticosteroids, methotrexate, and cyclosporine. Methotrexate and cyclosporine are equally effective in preventing GVHD. A combination of both drugs is better than either drug alone and results in an improved survival rate. The addition of corticosteroids to methotrexate, cyclosporine, or antithymocyte globulin is also more effective than single-drug therapy. Serial administration of intravenous immune globulin may contribute additional protection against acute GVHD. There is conflicting evidence concerning the prophylactic efficacy of pentoxifylline. Elimination of T lymphocytes from the donor marrow before transplantation has been associated with less GVHD but a higher incidence of graft failure. Total elimination of GVHD in patients with leukemia may cause loss of a graft-versus-leukemia effect, resulting in increased relapse rates and decreased long-term survival. Promising experimental prophylactic agents include thalidomide, zolimomab aritox, tacrolimus, antibodies to cytokines involved in the pathogenesis of GVHD, and monoclonal antibodies against cytokine receptors on T lymphocytes. Current research efforts are also directed toward eliminating GVHD without compromising the graft-versus-leukemia effect.

L13 ANSWER 6 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1994134937 EMBASE  
TITLE: Workshop 4. Reaction and nerve damage.  
AUTHOR: Naafs, B.; Rea, T.H.; Mukherjee, R.; Aguas, A.P.;  
Bell-Krotoski, J.; Bjune, A.; Das, P.K.; Faber, W.R.;  
Fukunishi, Y.; Kaleab, B.; Katoch, K.; Lehman, L.;  
Lockwood, D.; Marchese, A.; Marchese, L.C.M.; Miko, T.L.;  
Parida, S.K.; Rose, P.; Salafia, A.; et. al.  
SOURCE: International Journal of Leprosy, (1993) Vol. 61,  
No. 4 SUPPL., pp. 731-732.  
ISSN: 0148-916X CODEN: IJLEAG  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)  
FILE SEGMENT: 026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
004 Microbiology: Bacteriology, Mycology, Parasitology  
and Virology  
005 General Pathology and Pathological Anatomy  
008 Neurology and Neurosurgery  
LANGUAGE: English  
ENTRY DATE: Entered STN: 25 May 1994  
Last Updated on STN: 25 May 1994

L13 ANSWER 7 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993197423 EMBASE  
TITLE: Techniques of harvesting and cryopreservation of stem cells.  
AUTHOR: Meagher, R.C., Dr. (correspondence); Herzig, R.H.  
CORPORATE SOURCE: Hoxworth Blood Center, Cincinnati University Medical Center, 3130 Highland Avenue, Cincinnati, OH 45267-0055, United States.  
SOURCE: Hematology/Oncology Clinics of North America, (1993 ) Vol. 7, No. 3, pp. 501-533.  
ISSN: 0889-8588 CODEN: HCNAEQ  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 025 Hematology  
030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 8 Aug 1993  
Last Updated on STN: 8 Aug 1993

AB Improved marrow processing techniques and in vitro marrow manipulations are revolutionizing the clinical application of both allogeneic and autologous bone marrow transplantation. The rapid evolution of clinically useful laboratory techniques now necessitates more sophisticated laboratory support of bone marrow transplantation.

L13 ANSWER 8 OF 180 MEDLINE on STN DUPLICATE 4  
ACCESSION NUMBER: 1993329195 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8335978  
TITLE: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.  
AUTHOR: Sampaio E P; Kaplan G; Miranda A; Nery J A; Miguel C P; Viana S M; Sarno E N  
CORPORATE SOURCE: Leprosy Unit, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.  
CONTRACT NUMBER: AI-22616 (United States NIAID NIH HHS)  
SOURCE: The Journal of infectious diseases, (1993 Aug) Vol. 168, No. 2, pp. 408-14.



Journal code: 0413675. ISSN: 0022-1899. L-ISSN: 0022-1899.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals; AIDS  
ENTRY MONTH: 199308  
ENTRY DATE: Entered STN: 3 Sep 1993  
Last Updated on STN: 3 Sep 1993  
Entered Medline: 24 Aug 1993

AB Immunologic and clinical manifestations of erythema nodosum leprosum (ENL) and their response to thalidomide therapy were evaluated. Circulating tumor necrosis factor-alpha (TNF alpha) levels were assayed in serum obtained from lepromatous leprosy patients at diagnosis, during multidrug therapy, at the onset of ENL episodes, and during treatment with thalidomide. Patients with systemic ENL demonstrated the highest serum TNF alpha levels, which decreased significantly during thalidomide treatment. Serum TNF alpha in nonreactional patients was associated with mild flu-like symptoms and local inflammatory lesions. Serum interferon-gamma (IFN-gamma) was also elevated in patients with high TNF alpha levels. Thalidomide therapy reduced not only serum TNF alpha levels and the clinical symptoms but also the dermal infiltration of polymorphonuclear leukocytes and T cells. The expression of intercellular adhesion molecule 1 and major histocompatibility complex class II antigens on the epidermal keratinocytes was also down-regulated. These results indicate that the thalidomide-induced alleviation of clinical symptoms of ENL was associated with a reduction of TNF alpha levels.

L13 ANSWER 9 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1994042291 EMBASE  
TITLE: Workshop 4 - Reaction and nerve damage.  
AUTHOR: Naafs, B.; Rea, T.H.; Mukherjee, R.; Aguas, A.P.;  
Bell-Krotoski, J.; Bjune, A.; Das, P.K.; Faber, W.R.;  
Fukunishi, Y.; Kaleab, B.; Katoch, K.; Lehman, L.;  
Lockwood, D.; Marchese, A.; Marchese, L.C.M.; Miko, T.L.;  
Parida, S.K.; Rose, P.; Salafia, A.; et. al.  
SOURCE: Leprosy Review, (1993) Vol. 64, No. 4, pp.  
379-380.  
ISSN: 0305-7518 CODEN: LEREEA  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)  
FILE SEGMENT: 037 Drug Literature Index  
004 Microbiology: Bacteriology, Mycology, Parasitology  
and Virology  
LANGUAGE: English  
ENTRY DATE: Entered STN: 20 Feb 1994  
Last Updated on STN: 20 Feb 1994

L13 ANSWER 10 OF 180 MEDLINE on STN DUPLICATE 5  
ACCESSION NUMBER: 1993208191 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8457614  
TITLE: Acute and chronic graft-versus-host disease.  
AUTHOR: Vogelsang G B  
CORPORATE SOURCE: Johns Hopkins Oncology Center, Baltimore, Maryland.  
SOURCE: Current opinion in oncology, (1993 Mar) Vol. 5,  
No. 2, pp. 276-81. Ref: 18  
Journal code: 9007265. ISSN: 1040-8746. L-ISSN: 1040-8746.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199304  
ENTRY DATE: Entered STN: 14 May 1993  
Last Updated on STN: 14 May 1993  
Entered Medline: 27 Apr 1993

AB Acute graft-versus-host disease is a two-step process. First, allorecognition of histocompatibility antigen activates T lymphocytes, which releases several cytokines, including interleukin-1 and tumor necrosis factor. Understanding of this activity resulted in new therapeutic approaches. Chronic graft-versus-host disease remains a very frequent and difficult problem to treat. Thalidomide was introduced as therapy for chronic graft-versus-host disease. Although basic research reported this year had no common theme, progress was made in many areas.

L13 ANSWER 11 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993111766 EMBASE  
TITLE: Transplantation: Editorial overview.  
AUTHOR: Santos, G.W., Dr. (correspondence)  
CORPORATE SOURCE: Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, MD 21205, United States.  
SOURCE: Current Opinion in Oncology, (1993) Vol. 5, No. 2, pp. 253-254.  
ISSN: 1040-8746 CODEN: CUOOE8  
COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review; (Review)  
FILE SEGMENT: 016 Cancer  
026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
LANGUAGE: English  
ENTRY DATE: Entered STN: 16 May 1993  
Last Updated on STN: 16 May 1993

L13 ANSWER 12 OF 180 MEDLINE on STN DUPLICATE 6

ACCESSION NUMBER: 1993222804 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8467293  
TITLE: Thalidomide as therapy for intestinal chronic GVHD.  
AUTHOR: Lopez J; Ulibarrena C; Garcia-Larana J; Odriozola J; Perez de Oteyza J; Sastre J L; Navarro J L  
SOURCE: Bone marrow transplantation, (1993 Mar) Vol. 11, No. 3, pp. 251-2.  
Journal code: 8702459. ISSN: 0268-3369. L-ISSN: 0268-3369.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: (CASE REPORTS)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 199305  
ENTRY DATE: Entered STN: 21 May 1993  
Last Updated on STN: 21 May 1993  
Entered Medline: 7 May 1993

L13 ANSWER 13 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993186414 EMBASE  
TITLE: In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum.

AUTHOR: Santos, D.O. (correspondence); Suffys, P.N.; Bonifacio, K.;  
 Marques, M.A.; Sarno, E.N.  
 CORPORATE SOURCE: Dept. of Cellular/Molecular Biology, Federal Fluminense  
 University, Avenida Barros-Terra s/n, Valonguinho 20400,  
 Niteroi, RJ, Brazil.  
 SOURCE: Clinical Immunology and Immunopathology, (1993)  
 Vol. 67, No. 3 I, pp. 199-203.  
 ISSN: 0090-1229 CODEN: CLIIAT  
 COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article  
 FILE SEGMENT: 013 Dermatology and Venereology  
 026 Immunology, Serology and Transplantation  
 037 Drug Literature Index  
 004 Microbiology: Bacteriology, Mycology, Parasitology  
 and Virology  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 ENTRY DATE: Entered STN: 8 Aug 1993  
 Last Updated on STN: 8 Aug 1993

AB The production of tumor necrosis factor (TNF) by Mycobacterium  
 leprae- stimulated phagocyte cells, isolated from lepromatous leprosy  
 patients (LL) and normal individuals, was evaluated, using the highly  
 TNF-sensitive mouse fibro-sarcoma cell line WEHI164c113. Mononuclear  
 cells, isolated from all individuals studied, showed a low level of  
 spontaneous TNF production, except for patients undergoing erythema  
 nodosum leprosum (ENL), in which we found significantly higher levels of  
 TNF. Addition of M. leprae to the phagocyte cell culture enhanced TNF  
 production in all groups studied, except in the group with untreated  
 leprosy patients. Strongest M. leprae-induced TNF release was found in  
 mononuclear cell cultures derived from ENL patients. Patients in the  
 postreactional state showed significantly higher TNF levels than healthy  
 controls. These findings support the idea that TNF plays a key role in  
 the complex symptomatology of ENL.

L13 ANSWER 14 OF 180 MEDLINE on STN DUPLICATE 7  
 ACCESSION NUMBER: 1994232213 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 8177242  
 TITLE: Inhibition of tumor necrosis factor-alpha by  
 thalidomide in magnesium deficiency.  
 AUTHOR: Weglicki W B; Stafford R E; Dickens B F; Mak I T; Cassidy M  
 M; Phillips T M  
 CORPORATE SOURCE: Department of Medicine, George Washington University  
 Medical Center, Washington, DC 20037.  
 CONTRACT NUMBER: P01-HL-38079 (United States NHLBI NIH HHS)  
 R01-49232 (United States PHS HHS)  
 SOURCE: Molecular and cellular biochemistry, (1993 Dec 22)  
 Vol. 129, No. 2, pp. 195-200.  
 Journal code: 0364456. ISSN: 0300-8177. L-ISSN: 0300-8177.  
 PUB. COUNTRY: Netherlands  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; AIDS  
 ENTRY MONTH: 199406  
 ENTRY DATE: Entered STN: 20 Jun 1994  
 Last Updated on STN: 20 Jun 1994  
 Entered Medline: 7 Jun 1994

AB The effect of thalidomide on circulating cytokines and  
 myocardial lesion formation was investigated in Mg-deficient rats. After  
 two weeks on a Mg-deficient diet, rats show an increase in circulating  
 levels of tumor necrosis factor-alpha and interleukin 1.  
 Thalidomide (1 mg/day) caused a complete inhibition of the

increase in circulating tumor necrosis factor-alpha levels, without having an effect on interleukin 1. However, a marked increase in cardiomyopathic lesion formation was observed in Mg-deficient animals treated with thalidomide; possible mechanisms for thalidomide's enhancement of myocardial injury are discussed.

L13 ANSWER 15 OF 180 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN  
ACCESSION NUMBER: 1993:260524 BIOSIS  
DOCUMENT NUMBER: PREV199344122674  
TITLE: Is there an effective therapy for chronic graft-versus-host disease?.  
AUTHOR(S): Schiller, G. [Reprint author]; Gale, R. P.  
CORPORATE SOURCE: Div. Hematology/Oncology, UCLA Sch. Med., Los Angeles, CA 0024-1678, USA  
SOURCE: Bone Marrow Transplantation, (1993) Vol. 11, No. 3, pp. 189-192.  
ISSN: 0268-3369.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 27 May 1993  
Last Updated on STN: 27 May 1993

L13 ANSWER 16 OF 180 MEDLINE on STN  
ACCESSION NUMBER: 1993360618 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8355553  
TITLE: [Treatment with thalidomide and production of tumor necrosis factor alpha].  
Terapeutica con talidomida y produccion del factor de necrosis tumoral alfa.  
AUTHOR: Pizarro A; Pinilla J; Garcia-Tobaruela A  
SOURCE: Medicina clinica, (1993 Jun 19) Vol. 101, No. 4, pp. 158.  
Journal code: 0376377. ISSN: 0025-7753. L-ISSN: 0025-7753.  
PUB. COUNTRY: Spain  
DOCUMENT TYPE: Commentary  
Letter  
LANGUAGE: Spanish  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 199309  
ENTRY DATE: Entered STN: 8 Oct 1993  
Last Updated on STN: 3 Feb 1997  
Entered Medline: 17 Sep 1993

L13 ANSWER 17 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN  
ACCESSION NUMBER: 1993248592 EMBASE  
TITLE: [Therapy with thalidomide and tumor necrosis factor alpha production [2]].  
TERAPEUTICA CON TALIDOMIDA Y PRODUCCION DEL FACTOR DE NECROSIS TUMORAL ALFA [2].  
AUTHOR: Pizarro, A. (correspondence); Pinilla, J.; Garcia-Tobaruela, A.  
CORPORATE SOURCE: Servicio de Dermatologia, Hospital La Paz, Madrid, Spain.  
SOURCE: Medicina Clinica, (1993) Vol. 101, No. 4, pp. 158.  
ISSN: 0025-7753 CODEN: MCLBA2  
COUNTRY: Spain  
DOCUMENT TYPE: Journal; Letter  
FILE SEGMENT: 026 Immunology, Serology and Transplantation  
029 Clinical and Experimental Biochemistry  
037 Drug Literature Index

LANGUAGE: Spanish; Castilian  
ENTRY DATE: Entered STN: 26 Sep 1993  
Last Updated on STN: 26 Sep 1993

L13 ANSWER 18 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993058292 EMBASE  
TITLE: Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.  
AUTHOR: Szer, J., Dr. (correspondence); Grigg, A.P.; Phillips, G.L.; Sheridan, W.P.  
CORPORATE SOURCE: Clin Haematol Bone Marrow Transplant, Alfred Hospital, Commercial Road, Prahran, VIC 3181, Australia.  
SOURCE: Bone Marrow Transplantation, (1993) Vol. 11, No. 2, pp. 109-111.  
ISSN: 0268-3369 CODEN: BMTRE9  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 016 Cancer  
025 Hematology  
026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 21 Mar 1993  
Last Updated on STN: 21 Mar 1993

AB Four patients with acute myeloid leukaemia relapsed within 6 months of allogeneic BMT. Three patients were treated with cytosine arabinoside and amsacrine while the fourth received no chemotherapy. All patients received infusions of leucocytes obtained by repeated leukapheresis from the original bone marrow donor. Three patients developed GVHD requiring immunosuppressive therapy. One of these achieved a complete remission which has been sustained for more than 1 year with 100% donor haematopoiesis. The other patients died with persistent leukaemia 45-134 days after the infusions of donor cells. We conclude that the addition of marrow donor leucocytes to salvage chemotherapy may produce durable remissions in patients with acute myeloid leukaemia relapsing after BMT and that this may be due to a graft-versus-leukaemia effect.

L13 ANSWER 19 OF 180 MEDLINE on STN

ACCESSION NUMBER: 1993226612 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8469665  
TITLE: [Sclerodermatous cutaneous reaction of graft vs host disease treated with thalidomide].  
Reaction cutanee sclerodermiforme du greffon contre l'hôte traitée par thalidomide.  
AUTHOR: Pedailles S; Troussard X; Launay V; Bazin A; Sentias C; Surbled M  
SOURCE: Presse medicale (Paris, France : 1983), (Jan 2-16 1993) Vol. 22, No. 1, pp. 37.  
Journal code: 8302490. ISSN: 0755-4982. L-ISSN: 0755-4982.  
PUB. COUNTRY: France  
DOCUMENT TYPE: (CASE REPORTS)  
Letter  
LANGUAGE: French  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 199305  
ENTRY DATE: Entered STN: 21 May 1993  
Last Updated on STN: 21 May 1993  
Entered Medline: 12 May 1993

L13 ANSWER 20 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993041776 EMBASE  
TITLE: [Sclerodermatous skin reaction in graft-versus-host disease treated with thalidomide [1]].  
REACTION CUTANEE SCLERODERMIFORME DU GREFFON CONTRE L'HOTE TRAITEE PAR THALIDOMIDE [1].  
AUTHOR: Pedailles, S. (correspondence); Troussard, X.; Launay, V.; Bazin, A.; Sentias, C.; Surbled, M.  
CORPORATE SOURCE: Service de Dermatologie, Hopital Pasteur, Rue du Val-de-Saire, F 50102 Cherbourg, France.  
SOURCE: Presse Medicale, (1993) Vol. 22, No. 1, pp. 37.  
ISSN: 0755-4982 CODEN: PRMEEM  
COUNTRY: France  
DOCUMENT TYPE: Journal; Letter  
FILE SEGMENT: 013 Dermatology and Venereology  
026 Immunology, Serology and Transplantation  
030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
LANGUAGE: French  
ENTRY DATE: Entered STN: 26 Feb 1993  
Last Updated on STN: 26 Feb 1993

L13 ANSWER 21 OF 180 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1994:39926 BIOSIS  
DOCUMENT NUMBER: PREV199497052926  
TITLE: Lymphocyte depletion in bone marrow transplantation: Will modulation of graft-versus-host disease prove to be superior to prevention?.  
AUTHOR(S): Noga, Stephen J. [Reprint author]; Hess, Allan D.  
CORPORATE SOURCE: Bone Marrow Transplantation Program, Johns Hopkins Oncol. Cent., Room 3-127, 600 N. Wolfe St., Baltimore, MD 21287-8985, USA  
SOURCE: Seminars in Oncology, (1993) Vol. 20, No. 5  
SUPPL. 6, pp. 28-33.  
CODEN: SOLGAV. ISSN: 0093-7754.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Feb 1994  
Last Updated on STN: 3 Feb 1994

L13 ANSWER 22 OF 180 MEDLINE on STN

ACCESSION NUMBER: 1993163635 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8433015  
TITLE: Recent advances in cytokine therapy in leprosy.  
AUTHOR: Kaplan G  
CORPORATE SOURCE: Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, NY 10021-6399.  
SOURCE: The Journal of infectious diseases, (1993 Mar)  
Vol. 167 Suppl 1, pp. S18-22. Ref: 18  
Journal code: 0413675. ISSN: 0022-1899. L-ISSN: 0022-1899.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199303  
ENTRY DATE: Entered STN: 2 Apr 1993  
Last Updated on STN: 2 Apr 1993  
Entered Medline: 18 Mar 1993

AB Lepromatous leprosy is characterized by a selective anergy to Mycobacterium leprae and its antigens. The inadequate immune response and the resulting reduced interferon-gamma (IFN-gamma) production lead to a lack of macrophage activation and unrestricted bacterial growth. Purified protein derivative of tuberculin induced a normal local immune response in many lepromatous leprosy patients. Interleukin-2 induced an accelerated equivalent of an antigen response in the skin. In both, monocytes and T cells were recruited, and changes in keratinocytes, including expression of major histocompatibility complex class II antigens, were induced. Skin macrophages appeared to be activated and bacteria were eliminated. Similar effects were generated by IFN-gamma, a more distal molecule in the immune response. Cytokine treatment induced large amounts of tumor necrosis factor-alpha, which is toxic in this context but can be selectively down-regulated by thalidomide without interfering with other monocyte cytokines necessary for normal immune function.

L13 ANSWER 23 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993261377 EMBASE  
TITLE: Thalidomide tested for treatment of AIDS.  
SOURCE: U.S. Pharmacist, (1993) Vol. 18, No. 8, pp. 14.  
ISSN: 0148-4818 CODEN: USPHD5  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Note  
FILE SEGMENT: 026 Immunology, Serology and Transplantation  
030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology  
LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Oct 1993  
Last Updated on STN: 3 Oct 1993

L13 ANSWER 24 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993056371 EMBASE  
TITLE: Recent advances in cytokine therapy in leprosy.  
AUTHOR: Kaplan, G., Dr. (correspondence)  
CORPORATE SOURCE: Cellular Physiology/Immunology Lab., Rockefeller University, 1230 York Ave., New York, NY 10021-6399, United States.  
SOURCE: Journal of Infectious Diseases, (1993) Vol. 167, No. 3 SUPPL., pp. S18-S22.  
ISSN: 0022-1899 CODEN: JIDIAQ  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)  
FILE SEGMENT: 037 Drug Literature Index  
038 Adverse Reactions Titles  
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 21 Mar 1993  
Last Updated on STN: 21 Mar 1993

AB Lepromatous leprosy is characterized by a selective anergy to Mycobacterium leprae and its antigens. The inadequate immune response and the resulting reduced interferon- $\gamma$  (IFN- $\gamma$ ) production lead to a lack of macrophage activation and unrestricted bacterial growth. Purified protein derivative of tuberculin induced a normal local immune response in many lepromatous leprosy patients. Interleukin-2 induced an accelerated equivalent of an antigen response in the skin. In both,

monocytes and T cells were recruited, and changes in keratinocytes, including expression of major histocompatibility complex class II antigens, were induced. Skin macrophages appeared to be activated and bacteria were eliminated. Similar effects were generated by IFN- $\gamma$ , a more distal molecule in the immune response. Cytokine treatment induced large amounts of tumor necrosis factor- $\alpha$ , which is toxic in this context but can be selectively downregulated by thalidomide without interfering with other monocyte cytokines necessary for normal immune function.

L13 ANSWER 25 OF 180 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993330940 EMBASE  
TITLE: Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.  
AUTHOR: Schwinghammer, T.L., Dr. (correspondence); Bloom, E.J.  
CORPORATE SOURCE: Dept. of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States.  
SOURCE: American Journal of Hospital Pharmacy, (1993)  
Vol. 50, No. 11, pp. 2429+2432.  
ISSN: 0002-9289 CODEN: AJHPA9  
COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review; (Review)  
FILE SEGMENT: 026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
ENTRY DATE: Entered STN: 12 Dec 1993  
Last Updated on STN: 12 Dec 1993

=> d his

(FILE 'HOME' ENTERED AT 11:21:08 ON 02 MAR 2010)

FILE 'REGISTRY' ENTERED AT 11:21:22 ON 02 MAR 2010

L1 29 S THALIDOMIDE  
L2 1 S THALIDOMIDE/CN  
L3 3 S 50-35-1/RN OR 841-67-8/RN OR 2614-06-4/RN

FILE 'CAPLUS, 1MOBILITY, 2MOBILITY, CEABA-VTB, CHEMLIST, CHEMSAFE, CIN, CSNB, HEALSAFE, HSDB, INSPEC, ITRD, MSDS-CCOHS, MSDS-OHS, NAPRALERT, PASCAL, POLLUAB, PROMT, RTECS, SCISEARCH' ENTERED AT 11:24:36 ON 02 MAR 2010

FILE 'CAPLUS' ENTERED AT 11:24:40 ON 02 MAR 2010

L4 3569 S L3  
L5 2230 S L4 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM? OR ?LEU  
L6 2 S L5 AND AD<19930301  
L7 2 DUP REM L6 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 11:27:01 ON 02 MAR 2010

FILE 'REGISTRY' ENTERED AT 11:27:11 ON 02 MAR 2010

SET SMARTSELECT ON  
L8 SEL L3 1- CHEM : 46 TERMS  
SET SMARTSELECT OFF

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 11:27:11 ON 02 MAR 2010

L9 24609 S L8  
L10 24609 S L9 OR L3



L11 13424 S L10 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM? OR ?LE  
L12 235 S L11 AND PD<19930301  
L13 180 DUP REM L12 (55 DUPLICATES REMOVED)

=> s l13 not necrosis  
L14 152 L13 NOT NECROSIS

=> s l14 and thalidomide/ti  
L15 53 L14 AND THALIDOMIDE/TI

=> s l15 not graft  
L16 45 L15 NOT GRAFT

=> d l16 1-45 ibib abs

L16 ANSWER 1 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1993243646 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 1300872  
TITLE: [Erythroleukemia in a patient with Behcet's  
disease under long-term thalidomide therapy].  
Erythroleucemie chez un patient ayant une maladie de Behcet  
et traite au long cours par thalidomide.  
AUTHOR: Louzir B; Othmani S; Gritli N; Beji M; Zidi B; M'Saddek F;  
Boussema E; Bahri M  
SOURCE: Annales de medecine interne, (1992) Vol. 143, No.  
7, pp. 479-80.  
Journal code: 0171744. ISSN: 0003-410X. L-ISSN: 0003-410X.  
PUB. COUNTRY: France  
DOCUMENT TYPE: (CASE REPORTS)  
Letter  
LANGUAGE: French  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 199305  
ENTRY DATE: Entered STN: 11 Jun 1993  
Last Updated on STN: 11 Jun 1993  
Entered Medline: 24 May 1993

L16 ANSWER 2 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1992034660 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 1933837  
TITLE: The thalidomide analog, EM 12, enhances  
1,2-dimethylhydrazine-induction of rat colon  
adenocarcinomas.  
AUTHOR: Gershbein L L  
CORPORATE SOURCE: Biochemistry and Oncology Sections, Northwest Institute for  
Medical Research, John F. Kennedy Health Care Corporation,  
Chicago, Illinois 60645.  
SOURCE: Cancer letters, (1991 Nov) Vol. 60, No. 2, pp.  
129-33.  
Journal code: 7600053. ISSN: 0304-3835. L-ISSN: 0304-3835.  
PUB. COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 199112  
ENTRY DATE: Entered STN: 24 Jan 1992  
Last Updated on STN: 6 Feb 1998  
Entered Medline: 2 Dec 1991

AB Young male Sprague-Dawley rats in 3 groups were fed a basal diet  
supplemented with 0.10 weight % each of thalidomide and its  
imide-analog of much higher teratogenicity, EM 12. Following an induction

period of 17 days on the diets, all animals were injected subcutaneously with 1,2-dimethylhydrazine at 20 mg/kg for a total of 20 weekly doses and killed on week 18 after the 20th injection. The total number of colon adenocarcinomas and their occurrence in the proximal and distal portions for the thalidomide-treated rats were similar to those of the respective controls. However, the EM 12-fed group elicited statistically significant increases both in the total and ascending colon-based adenocarcinomas as compared with the control findings, in keeping with its greater teratogenicity and embryotoxicity. The numbers of small intestinal adenocarcinomas were equally higher in the imide-fed groups in contrast to the control frequency.

L16 ANSWER 3 OF 45 MEDLINE on STN  
 ACCESSION NUMBER: 1991203215 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 2016904  
 TITLE: Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites.  
 AUTHOR: Hatfill S J; Fester E D; de Beer D P; Bohm L  
 CORPORATE SOURCE: Radiotherapy Department, Faculty of Medicine, University of Stellenbosch, Tygerberg, R.S.A.  
 SOURCE: Leukemia research, (1991) Vol. 15, No. 2-3, pp. 129-36.  
 Journal code: 7706787. ISSN: 0145-2126. L-ISSN: 0145-2126.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; AIDS  
 ENTRY MONTH: 199105  
 ENTRY DATE: Entered STN: 7 Jun 1991  
 Last Updated on STN: 3 Feb 1997  
 Entered Medline: 17 May 1991

AB The lineage and state of differentiation of cells in the mammalian haemopoietic compartment is associated with specific patterns of homeobox gene expression (EMBO J. 7, 2131, 1988). Agents which influence homeobox gene expression are thus of great interest in the study of human leukemias. Retinoic acid has direct regulatory actions on homeobox gene transcription (TIBS 158, 52, 1989; Differentiation 37, 773, 1988) and can induce select human leukemia cell lines to undergo terminal differentiation in vitro (Proc. natl Acad. Sci. U.S.A. 77, 2936, 1980). Retinoic acid is also a known teratogen for vertebrate foetal limb-bud development. Some of the teratogenic effects are duplicated by the drug Thalidomide (Embryopathic Activity of Drugs, Little Brown, Boston, p. 167, 1965; Haematological Cytology, Wolf Med. Pub. Ltd, London, p. 118, 1982). To investigate Thalidomide for other retinoid-like effects, we exposed cultures of human leukemia K562 cells to the metabolites generated in a Thalidomide hepatic-microsomal enzyme drug metabolizing system (Proc. natl Acad. Sci. U.S.A. 78, 2545, 1981). Here we report evidence that a single 2 h pulse-exposure to Thalidomide metabolites, induces K562 cells to undergo morphological differentiation in vitro. We also demonstrate a significant cytotoxic effect for these metabolites.

L16 ANSWER 4 OF 45 MEDLINE on STN  
 ACCESSION NUMBER: 1986123775 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 3945939  
 TITLE: Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450.  
 AUTHOR: Braun A G; Harding F A; Weinreb S L  
 SOURCE: Toxicology and applied pharmacology, (1986 Jan) Vol. 82, No. 1, pp. 175-9.

Journal code: 0416575. ISSN: 0041-008X. L-ISSN: 0041-008X.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (IN VITRO)  
Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 198603  
ENTRY DATE: Entered STN: 21 Mar 1990  
Last Updated on STN: 21 Mar 1990  
Entered Medline: 4 Mar 1986

AB A metabolite of thalidomide generated by hepatic microsomes inhibited the attachment of tumor cells to concanavalin A-coated polyethylene. Evidence that metabolite formation is mediated by microsomal cytochrome P-450 is presented. Microsomes incubated with thalidomide underwent a type I spectral shift. Metabolite formation was reduced or eliminated by carbon monoxide, SKF-525A, metyrapone, and N-octylamine. Superoxide dismutase treatment had no effect. Metabolite formation required microsomes and NADPH and was dependent on the length of 37 degrees C incubation. The metabolite could be isolated by successive hexane and chloroform extractions. It is likely the inhibitory thalidomide metabolite was generated by a minor cytochrome P-450 species. Whether this thalidomide metabolite is involved in the drug's teratogenic activity remains to be shown.

L16 ANSWER 5 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1986071093 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 2866599  
TITLE: Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes.  
AUTHOR: Braun A G; Weinreb S L  
SOURCE: Teratogenesis, carcinogenesis, and mutagenesis, (1985) Vol. 5, No. 3, pp. 149-58.  
Journal code: 8100917. ISSN: 0270-3211. L-ISSN: 0270-3211.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 198601  
ENTRY DATE: Entered STN: 21 Mar 1990  
Last Updated on STN: 3 Feb 1997  
Entered Medline: 21 Jan 1986

AB Thalidomide and two analogues, EM87 and EM12, inhibited the attachment of tumor cells to concanavalin A-coated surfaces only if the drugs were first incubated with hepatic microsomes and cofactors. Most agents that inhibit attachment are demonstrated teratogens. Thalidomide undergoes spontaneous hydrolysis to at least 12 products in saline buffered to a pH of greater than 7. These hydrolysis products did not inhibit attachment nor could they be activated to inhibitory products with hepatic microsomes. Similarly EM12 and EM 87 hydrolysis products were neither inhibitory nor substrates for activation. If the three drugs were incubated in buffered saline, there was a progressive decline in their ability to act as substrates for activation to an inhibitory product. It was possible to remove microsomes from the incubation mixture following drug activation by centrifugation. This microsome-free mixture inhibited cell attachment. When mouse ovarian tumor (MOT) cells were added to the microsome-free mixture, attachment was inhibited. However, if the activated drugs were incubated in saline, there was a progressive decline in their ability to inhibit attachment. Decay rates differed for the three compounds. At a pH of

7.4, thalidomide, EM87, and EM12 required 3 h, 1h and 6h, respectively, to decay to control levels. These relative rates of decay are consistent with the relative teratogenicity of the three drugs.

L16 ANSWER 6 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1984231518 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 6732864  
TITLE: Teratogen metabolism: activation of thalidomide and thalidomide analogues to products that inhibit the attachment of cells to concanavalin A coated plastic surfaces.  
AUTHOR: Braun A G; Weinreb S L  
SOURCE: Biochemical pharmacology, (1984 May 1) Vol. 33, No. 9, pp. 1471-7.  
Journal code: 0101032. ISSN: 0006-2952. L-ISSN: 0006-2952.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 198406  
ENTRY DATE: Entered STN: 20 Mar 1990  
Last Updated on STN: 20 Mar 1990  
Entered Medline: 22 Jun 1984

AB Thalidomide metabolites inhibited the attachment of tumor cells to concanavalin A coated polyethylene surfaces. Thalidomide, itself, was non-inhibitory. Thalidomide activation to inhibitory products required hepatic microsomes, an NADPH-generating system, and molecular oxygen. Production of inhibitory metabolites was unaffected by either epoxide hydrolase or 1,2-epoxy-3,3,3-trichloropropane (TCPO), an inhibitor of epoxide hydrolase endogenous to hepatic S9 fraction. Therefore, the attachment inhibitor was probably not an arene oxide. Inhibition was not accompanied by cytotoxicity, as judged by trypan blue exclusion. Although uninduced hepatic microsomes from mice, rats and dogs had similar abilities to activate thalidomide, microsomes from Aroclor 1254 induced rats were relatively inactive in the system. Inhibitory metabolites were generated from the thalidomide analogues EM8 , EM12 , EM16 , EM87 , EM136 , EM255 , E350 , phthalimide, phthalimido-phthalimide, indan, 1- indanone and 1,3- indandione . Glutarimide , glutamic acid and phthalic acid did not activate to inhibitory products.

L16 ANSWER 7 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1981184009 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 7225125  
TITLE: Thalidomide metabolite inhibits tumor cell attachment to concanavalin A coated surfaces.  
AUTHOR: Braun A G; Dailey J P  
CONTRACT NUMBER: CA-12662-07 (United States NCI NIH HHS)  
SOURCE: Biochemical and biophysical research communications, (1981 Feb 27) Vol. 98, No. 4, pp. 1029-34.  
Journal code: 0372516. ISSN: 0006-291X. L-ISSN: 0006-291X.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 198106  
ENTRY DATE: Entered STN: 16 Mar 1990  
Last Updated on STN: 3 Feb 1997  
Entered Medline: 25 Jun 1981

L16 ANSWER 8 OF 45 MEDLINE on STN  
 ACCESSION NUMBER: 1980142914 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 7360121  
 TITLE: [Coincidence of a thalidomide-induced  
 malformation and a lymphoma of high malignancy (author's  
 transl)].  
 Zusammentreffen einer Thalidomid-induzierten Fehlbildung  
 mit einem malignen Lymphom hohen Malignitätsgrades.  
 AUTHOR: Miller A; Schmidt C G; Horwitz A; Kosenow W  
 SOURCE: Monatsschrift für Kinderheilkunde, (1980 Jan)  
 Vol. 128, No. 1, pp. 27-9.  
 Journal code: 0400751. ISSN: 0026-9298. L-ISSN: 0026-9298.  
 PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of  
 DOCUMENT TYPE: (CASE REPORTS)  
 (ENGLISH ABSTRACT)  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: German  
 FILE SEGMENT: Priority Journals; AIDS  
 ENTRY MONTH: 198005  
 ENTRY DATE: Entered STN: 15 Mar 1990  
 Last Updated on STN: 15 Mar 1990  
 Entered Medline: 23 May 1980  
 AB The case history of a fifteen year old patient with Thalidomide  
 induced malformation who developed a lymphoma of high malignancy is  
 presented.

L16 ANSWER 9 OF 45 MEDLINE on STN  
 ACCESSION NUMBER: 1977253783 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 70617  
 TITLE: Thalidomide-type malformations and subsequent  
 osteosarcoma.  
 AUTHOR: Teppo L; Saxen E; Tervo T; Partio E; von Ronsdorff H;  
 Salmela J; Avikainen V; Isomaki M; Krees R  
 SOURCE: Lancet, (1977 Aug 20) Vol. 2, No. 8034, pp. 405.  
 Journal code: 2985213R. ISSN: 0140-6736. L-ISSN: 0140-6736.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: (CASE REPORTS)  
 Letter  
 LANGUAGE: English  
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
 ENTRY MONTH: 197710  
 ENTRY DATE: Entered STN: 14 Mar 1990  
 Last Updated on STN: 14 Mar 1990  
 Entered Medline: 20 Oct 1977

L16 ANSWER 10 OF 45 MEDLINE on STN  
 ACCESSION NUMBER: 1971133848 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 5401721  
 TITLE: [Immunodepressive action of thalidomide and  
 prednisolone in rats with experimentally induced  
 neoplasms].  
 Ricerche sull'azione immunodepressiva della talidomide e  
 del prednisolone in ratti portatori di neoplasie  
 sperimentamente indotte.  
 AUTHOR: Guidetti E; Moiraghi-Ruggenini A; Errigo E; Martelli M P  
 SOURCE: Il Cancro, (1969) Vol. 22, No. 5, pp. 503-12.  
 Journal code: 0421125. ISSN: 0008-5480. L-ISSN: 0008-5480.  
 PUB. COUNTRY: Italy  
 DOCUMENT TYPE: (COMPARATIVE STUDY)  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: Italian  
 FILE SEGMENT: Priority Journals

ENTRY MONTH: 197104  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 1 Jan 1990  
Entered Medline: 25 Apr 1971

L16 ANSWER 11 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1971034714 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 5758511  
TITLE: [Action of thalidomide on Drosophila: development  
and tumorigenesis. Comparison with potassium  
phthalate and some nonphthalic compounds].  
Actions de la thalidomide chez la drosophile:  
developpement et tumorigenese. Comparison avec le  
phtalate de potassium et quelques composes non phtaliques.  
AUTHOR: Baroche C  
SOURCE: Bulletin du cancer, (1968 Jul-Sep) Vol. 55, No.  
3, pp. 413-28.  
Journal code: 0072416. ISSN: 0007-4551. L-ISSN: 0007-4551.  
PUB. COUNTRY: France  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: French  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 197101  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 6 Feb 1998  
Entered Medline: 9 Jan 1971

L16 ANSWER 12 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1970131370 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 5417508  
TITLE: Potentiating effect of thalidomide on  
methylcholanthrene oncogenesis in mice.  
AUTHOR: Miura M; Southam C M; Wuest H  
SOURCE: Experientia, (1970 Mar 15) Vol. 26, No. 3, pp.  
305-6.  
Journal code: 0376547. ISSN: 0014-4754. L-ISSN: 0014-4754.  
PUB. COUNTRY: Switzerland  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 197004  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 1 Jan 1990  
Entered Medline: 20 Apr 1970

L16 ANSWER 13 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1969130016 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 5609395  
TITLE: [Thalidomide and experimental neoplasms  
].  
Talidomide e tumori sperimentali.  
AUTHOR: Moiraghi Ruggerini A; Errigo E  
SOURCE: Il Cancro, (1967) Vol. 20, No. 1, pp. 39-55.  
Journal code: 0421125. ISSN: 0008-5480. L-ISSN: 0008-5480.  
PUB. COUNTRY: Italy  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Italian  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196904  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 1 Jan 1990  
Entered Medline: 22 Apr 1969

L16 ANSWER 14 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1968326790 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 5631600  
TITLE: [Treatment of a 2nd degree astrocytoma with  
thalidomide (N-phthalylglutamic acid amide).  
Behandlung eines Astrocytomas II. Grades mit Thalidomid  
(N-Phthalylglutaminsäureimid).  
AUTHOR: Buelens I  
SOURCE: Arzneimittel-Forschung, (1967 May) Vol. 17, No.  
5, pp. 646-8.  
Journal code: 0372660. ISSN: 0004-4172. L-ISSN: 0004-4172.  
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: German  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196809  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 1 Jan 1990  
Entered Medline: 6 Sep 1968

L16 ANSWER 15 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1968274900 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 6014810  
TITLE: [Clinical observations in the influence of  
thalidomide in the treatment of a leiomyoma in a  
dog].  
Klinische Beobachtung über den Einfluss von Thalidomid bei  
der Behandlung eines Leiomyoms bei einem Hund.  
AUTHOR: Zwart D  
SOURCE: Arzneimittel-Forschung, (1966 Dec) Vol. 16, No.  
12, pp. 1688-9.  
Journal code: 0372660. ISSN: 0004-4172. L-ISSN: 0004-4172.  
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: German  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196807  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 1 Jan 1990  
Entered Medline: 29 Jul 1968

L16 ANSWER 16 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1968044021 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 4168246  
TITLE: [Thalidomide and cancer].  
Thalidomid und Tumor.  
AUTHOR: Muckter H; More E  
SOURCE: Arzneimittel-Forschung, (1966 Feb) Vol. 16, No.  
2, pp. 129-34.  
Journal code: 0372660. ISSN: 0004-4172. L-ISSN: 0004-4172.  
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: German  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196801  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 1 Jan 1990  
Entered Medline: 12 Jan 1968

L16 ANSWER 17 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1967176011 MEDLINE

DOCUMENT NUMBER: PubMed ID: 4291111  
TITLE: Tumour-incidence in progeny of  
thalidomide-treated mice.  
AUTHOR: Roe F J; Walters M A; Mitchley B C  
SOURCE: British journal of cancer, (1967 Jun) Vol. 21,  
No. 2, pp. 331-3.  
Journal code: 0370635. ISSN: 0007-0920. L-ISSN: 0007-0920.  
Report No.: NLM-PMC2008116.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196709  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 6 Feb 1998  
Entered Medline: 2 Sep 1967

L16 ANSWER 18 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1967045837 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 5924953  
TITLE: Effects of prednisolone and thalidomide on  
induced submandibular gland tumors in hamsters.  
AUTHOR: Chaudhry A P; Schmutz J A Jr  
SOURCE: Cancer research, (1966 Sep) Vol. 26, No. 9, pp.  
1884-6.  
Journal code: 2984705R. ISSN: 0008-5472. L-ISSN: 0008-5472.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196702  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 1 Jan 1990  
Entered Medline: 5 Feb 1967

L16 ANSWER 19 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1966169692 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 5887938  
TITLE: [Use of the imide of N-phthalylglutamic acid (  
thalidomide) in the symptomatic therapy of vomiting  
of many patients with malignant neoplasms or  
caused by the administration of mechlorethamine HCl].  
L'impiego dell'imide dell'acido N-ftalilglutammico  
(thalidomide) nella terapia sintomatica del vomito di molti  
pazienti affetti da neoplasie maligne o causato dalla  
somministrazione di cloridato di mecloretamina.  
AUTHOR: Traldi A; Vaccari G L; Davoli G  
SOURCE: Il Cancro, (1965) Vol. 18, No. 4, pp. 336-41.  
Journal code: 0421125. ISSN: 0008-5480. L-ISSN: 0008-5480.  
PUB. COUNTRY: Italy  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Italian  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196610  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 1 Jan 1990  
Entered Medline: 16 Oct 1966

L16 ANSWER 20 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1966136696 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 5883469  
TITLE: Thalidomide and tumor.



AUTHOR: Muckter H  
SOURCE: Antimicrobial agents and chemotherapy, (1965)  
Vol. 5, pp. 531-8.  
Journal code: 0116415.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (IN VITRO)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 196608  
ENTRY DATE: Entered STN: 1 Jan 1990  
Last Updated on STN: 3 Mar 2000  
Entered Medline: 13 Aug 1966

L16 ANSWER 21 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1965100633 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14296026  
TITLE: CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS  
WITH CANCER.  
AUTHOR: GRABSTALD H; GOLBEY R  
SOURCE: Clinical pharmacology and therapeutics, (1965  
May-Jun) Vol. 6, pp. 298-302.  
Journal code: 0372741. ISSN: 0009-9236. L-ISSN: 0009-9236.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 22 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1965100632 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14296025  
TITLE: THALIDOMIDE (N-  
PHTHALOYLGLUTAMIMIDE) IN THE TREATMENT OF ADVANCED  
CANCER.  
AUTHOR: OLSON K B; HALL T C; HORTON J; KHUNG C L; HOSLEY H F  
SOURCE: Clinical pharmacology and therapeutics, (1965  
May-Jun) Vol. 6, pp. 292-7.  
Journal code: 0372741. ISSN: 0009-9236. L-ISSN: 0009-9236.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 23 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964152365 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14194333  
TITLE: [STUDIES OF THE ANTITUMORAL ACTIVITY OF  
THALIDOMIDE].  
STUDI SULL'ATTIVITA ANTITUMORALE DELLA  
TALIDOMIDE.  
AUTHOR: GAETANI M  
SOURCE: Giornale italiano di chemioterapia, (1964 Apr-Jun)  
Vol. 11, pp. 83-6.  
Journal code: 17140055R. ISSN: 0017-0445. L-ISSN:

0017-0445.

PUB. COUNTRY: Italy  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Italian  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 24 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964127325 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14169347  
TITLE: THALIDOMIDE: EFFECTS ON EHRlich ASCITES  
TUMOR CELLS IN VITRO.  
AUTHOR: DIPAOLO J A; WENNER C E  
SOURCE: Science (New York, N.Y.), (1964 Jun 26) Vol. 144,  
pp. 1583.  
Journal code: 0404511. ISSN: 0036-8075. L-ISSN: 0036-8075.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

AB Thalidomide did not inhibit dehydrogenase activity or growth of Ehrlich ascites tumor cells in agar. When mixed with Ehrlich ascites tumor cells in vitro, thalidomide increased the mitotic activity. The effect of the thalidomide was not altered by the addition of nicotinic or folic acid, or by vitamin B(1) or B(6). Oxygen uptake by the tumor cells was not affected by thalidomide.

L16 ANSWER 25 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964115942 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14157974  
TITLE: [STUDIES IN REGARD TO THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE].  
ESTUDIOS EN TORNO AL POSIBLE EFECTO ANTI-NEOPL'ASICO DE LA TALIDOMIDA.  
AUTHOR: BACH A; BICHEL J; HEJGAARD J J  
SOURCE: Folia clinica internacional, (1963 Nov) Vol. 13,  
pp. 511-9.  
Journal code: 2984759R. ISSN: 0015-5527. L-ISSN: 0015-5527.  
PUB. COUNTRY: Spain  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Spanish  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 26 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964103669 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14145740  
TITLE: [CONFIRMED INEFFECTIVENESS OF THALIDOMIDE IN THE THERAPY OF TUMORS].  
CONFERMATA L'INEFFICACIA DELLA TALIDOMIDE NELLA TERAPIA DEI TUMORI.

AUTHOR: ALLEGRI A  
SOURCE: Gazzetta medica italiana, (1964 Apr) Vol. 123,  
pp. 124-7.  
Journal code: 0370730. ISSN: 0393-3660. L-ISSN: 0393-3660.  
PUB. COUNTRY: Italy  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Italian  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 27 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964091890 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14133998  
TITLE: EFFECT OF THALIDOMIDE ON TRANSPLANTABLE MOUSE,  
RAT, AND HAMSTER TUMORS.  
AUTHOR: SUGIURA K; WUEST H M  
SOURCE: Gann = Gan, (1964 Feb) Vol. 55, pp. 57-60.  
Journal code: 8214471. ISSN: 0016-450X. L-ISSN: 0016-450X.  
PUB. COUNTRY: Japan  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 28 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964081361 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14123612  
TITLE: [TREATMENT OF EXPERIMENTAL TUMORS WITH  
THALIDOMIDE].  
TRATTAMENTO DI TUMORI SPERIMENTALI CON  
TALIDOMIDE.  
AUTHOR: PAGNINI G; DICARLO R  
SOURCE: Bollettino della Societa italiana di biologia sperimentale,  
(1963 Nov 30) Vol. 39, pp. 1360-3.  
Journal code: 7506962. ISSN: 0037-8771. L-ISSN: 0037-8771.  
PUB. COUNTRY: Italy  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Italian  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 29 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964055406 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14097727  
TITLE: THALIDOMIDE AND NEOPLASIA.  
AUTHOR: ROE F J; MITCHLEY B C  
SOURCE: Nature, (1963 Dec 7) Vol. 200, pp. 1016-7.  
Journal code: 0410462. ISSN: 0028-0836. L-ISSN: 0028-0836.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612

ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 30 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964039115 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14081473  
TITLE: [CLINICAL IMPROVEMENTS OBTAINED IN ADVANCED CANCER  
PATIENTS WITH TREATMENT WITH THALIDOMIDE  
ASSOCIATED WITH HORMONES].  
MELHORAS CL'INICAS OBTIDAS EM DOENTES CANCEROSOS  
AVAN CADOS COM TRATAMENTO PELA TALIDOMIDA ASSOCIADA A HORM  
ONIOS.  
AUTHOR: MAUAD M J  
SOURCE: Anais paulistas de medicina e cirurgia, (1963 Jul)  
Vol. 86, pp. 13-40.  
Journal code: 0373070. ISSN: 0003-245X. L-ISSN: 0003-245X.  
PUB. COUNTRY: Brazil  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Portuguese  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 31 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1964038123 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14080481  
TITLE: STUDIES ON THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF  
THALIDOMIDE.  
AUTHOR: BACH A; BICHEL J; HEJGAARD J J  
SOURCE: Acta pathologica et microbiologica Scandinavica,  
(1963) Vol. 59, pp. 491-9.  
Journal code: 7508471. ISSN: 0365-5555. L-ISSN: 0365-5555.  
PUB. COUNTRY: Denmark  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199612  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Dec 1996

L16 ANSWER 32 OF 45 MEDLINE on STN  
ACCESSION NUMBER: 1962221950 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14029957  
TITLE: Absence of carcinostatic effect of thalidomide  
with respect to 2 grafted tumors.  
AUTHOR: JURET P; AUBERT C  
SOURCE: Comptes rendus des seances de la Societe de biologie et de  
ses filiales, (1963 Jun 10) Vol. 157, pp. 246-9.  
Journal code: 7505439. ISSN: 0037-9026. L-ISSN: 0037-9026.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: French  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199811  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Nov 1998

L16 ANSWER 33 OF 45 MEDLINE on STN

ACCESSION NUMBER: 1962219992 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14028007  
TITLE: Effect of thalidomide on a variety of  
transplantable tumors.  
AUTHOR: DIPAOLO J A  
SOURCE: Cancer chemotherapy reports. Part 1, (1963 May)  
Vol. 29, pp. 99-102.  
Journal code: 7607105. ISSN: 0069-0112. L-ISSN: 0069-0112.  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: OLDMEDLINE; NONMEDLINE  
ENTRY MONTH: 199811  
ENTRY DATE: Entered STN: 16 Jul 1999  
Last Updated on STN: 16 Jul 1999  
Entered Medline: 1 Nov 1998

L16 ANSWER 34 OF 45 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1993024849 EMBASE  
TITLE: [Acute myeloid leukemia in a Behcet's disease  
patient under long-term thalidomide treatment].  
ERYTHROLEUCEMIE CHEZ UN PATIENT AYANT UNE MALADIE DE BEHCET  
ET TRAITE AU LONG COURS PAR THALIDOMIDE.  
AUTHOR: Louzir, B. (correspondence); Othmani, S.; Gritli, N.; Beji,  
M.; Zidi, B.; M'Saddek, F.; Boussema, E.; Bahri, M.  
CORPORATE SOURCE: Service de Medecine Interne, Hop. Mil. Principal  
d'Instruction, Montfleury 1089, Tunisia.  
SOURCE: Annales de Medecine Interne, (1992) Vol. 143, No.  
7, pp. 479-480.  
ISSN: 0003-410X CODEN: AMDIBO  
COUNTRY: France  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 016 Cancer  
025 Hematology  
030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
052 Toxicology  
LANGUAGE: French  
ENTRY DATE: Entered STN: 21 Feb 1993  
Last Updated on STN: 21 Feb 1993

L16 ANSWER 35 OF 45 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1989135904 EMBASE  
TITLE: Thalidomide in dermatology.  
AUTHOR: Saul, A.  
CORPORATE SOURCE: Servicio de Dermatologia del Hospital General de Mexico,  
Mexico City, Mexico.  
SOURCE: Dermatologia Revista Mexicana, (1988) Vol. 32,  
No. 2, pp. 39-41.  
ISSN: 0185-4038 CODEN: DERMAE  
COUNTRY: Mexico  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 013 Dermatology and Venereology  
037 Drug Literature Index  
LANGUAGE: Spanish; Castilian  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 12 Dec 1991  
Last Updated on STN: 12 Dec 1991

AB Thalidomide synthesized in Germany, was widely used as a  
sedative until its teratogenic effects were detected. For that this drug  
was stigmatized. Its rehabilitation began in 1965 when it was used in

some malignant tumors and survival homografts. Sheskin demonstrated its usefulness in the treatment of lepra reaction and afterwards thalidomide has proved to be useful in polymorphous light eruption, discoid lupus erythematosus, Behcet's disease, aphtosis, Hyde's nodular prurigo and other dermatological condiction of difficult therapy. Therefore it is thought that thalidomide, in other times a cursed drug, merits another opportunity to be useful.

L16 ANSWER 36 OF 45 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1980156487 EMBASE  
TITLE: Thalidomide metabolite inhibits tumor cell attachment to lectin coated surfaces.  
AUTHOR: Braun, A.G.; Dailey, J.P.  
CORPORATE SOURCE: Dept. Radiat. Ther., Harvard Med. Sch., Boston, Mass., United States.  
SOURCE: Teratology, (1980) Vol. 21, No. 2, pp. 29A.  
ISSN: 0040-3709 CODEN: TJADAB  
COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
LANGUAGE: English  
ENTRY DATE: Entered STN: 9 Dec 1991  
Last Updated on STN: 9 Dec 1991

L16 ANSWER 37 OF 45 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1978088312 EMBASE  
TITLE: Quantitative structure activity relationship (QSAR) and rational drug design for some antineoplastic thalidomide and glutarimide derivatives.  
AUTHOR: De, A.U.; Pal, D.  
CORPORATE SOURCE: Dept. Pharm., Jadavpur Univ., Calcutta, India.  
SOURCE: Journal of the Indian Chemical Society, (1976) Vol. 53, No. 10, pp. 1049-1052.  
ISSN: 0019-4522 CODEN: JICSAH  
COUNTRY: India  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
LANGUAGE: English

L16 ANSWER 38 OF 45 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1981:110892 BIOSIS  
DOCUMENT NUMBER: PREV198121045888; BR21:45888  
TITLE: THALIDOMIDE METABOLITE INHIBITS TUMOR CELL ATTACHMENT TO LECTIN COATED SURFACES.  
AUTHOR(S): BRAUN A G [Reprint author]; DAILEY J P  
CORPORATE SOURCE: DEP RADIAT THER, HARV MED SCH, BOSTON, MASS, USA  
SOURCE: Teratology, (1980) Vol. 21, No. 2, pp. 29A.  
Meeting Info.: 20TH ANNUAL MEETING OF THE TERATOLOGY SOCIETY, PORTSMOUTH, N.H., USA, JUNE 8-12, 1980.  
TERATOLOGY.  
CODEN: TJADAB. ISSN: 0040-3709.  
DOCUMENT TYPE: Conference; (Meeting)  
FILE SEGMENT: BR  
LANGUAGE: ENGLISH

L16 ANSWER 39 OF 45 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1969:87751 BIOSIS  
DOCUMENT NUMBER: PREV196950025751; BA50:25751

TITLE: ANTI TUMOR EFFECT OF THALIDOMIDE ANTI  
NEOPLASTIC.  
AUTHOR(S): KLEINE R  
SOURCE: Naturwissenschaftliche Rundschau, (1967) Vol. 20,  
No. 5, pp. 210.  
CODEN: NARSAC. ISSN: 0028-1050.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: Unavailable

L16 ANSWER 40 OF 45 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on  
STN

ACCESSION NUMBER: 1965:11579 BIOSIS  
DOCUMENT NUMBER: PREV19654600011581; BA46:11581  
TITLE: Thalidomide and cancer. An official  
report of Ministry of Health, State of Israel.  
AUTHOR(S): ISRAEL MINISTRY OF HEALTH  
SOURCE: HAROKEACH HAIVRI, (1963) Vol. 9, pp. 359-361.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: Unavailable  
ENTRY DATE: Entered STN: May 2007  
Last Updated on STN: May 2007

AB English and Hebrew.[long dash]The improvement in the general condition of  
the patient with cancer following the administration of  
thalidomide is due to the great potency of its tranquilizing  
effect. ABSTRACT AUTHORS: Authors

L16 ANSWER 41 OF 45 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on  
STN

ACCESSION NUMBER: 1964:78265 BIOSIS  
DOCUMENT NUMBER: PREV19644500078272; BA45:78272  
TITLE: Thalidomide and neoplasia (mice.).  
AUTHOR(S): ROE, F. J. C.; MITCHLEY, B. C. V.  
CORPORATE SOURCE: Roy Cancer Hosp., London, England  
SOURCE: NATURE, (1963) Vol. 200, No. 4910, pp. 1016-1017.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: Unavailable  
ENTRY DATE: Entered STN: May 2007  
Last Updated on STN: May 2007

L16 ANSWER 42 OF 45 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on  
STN

ACCESSION NUMBER: 1964:47172 BIOSIS  
DOCUMENT NUMBER: PREV19644500047177; BA45:47177  
TITLE: A rare case of developmental disturbance with an analysis  
of the chromosomes, possibly due to prenatal damage by  
thalidomide.  
Original Title: Ein seltener Fall von Entwicklungstorungen  
- moglicherweise auf Grund pranataler Thalidomidschadigung  
mit Chromosomenanalyse.  
AUTHOR(S): BENDA, CLEMENS E.; BAUGHMAN, A.  
CORPORATE SOURCE: (Max-Plank Inst. Psychiat., Munich, W. Germany  
SOURCE: MED WELT, (1963) Vol. 1963, No. 34, pp.  
1661-1664.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: Unavailable  
ENTRY DATE: Entered STN: May 2007  
Last Updated on STN: May 2007

AB A child of a mother, who had taken thalidomide during her

pregnancy, was born 1955 with a soft tumor at the back of the skull. The tumor was removed and diagnosed as a meningoencephalocele. Three weeks after birth a mild hydrocephalus developed and a capillary hematoma over the front and nose reaching to the upper lip. The child had also hypertelorism and coloboma of the eyes. The extremities, especially the hands, have extremely short index-fingers, and the hands showed the so-called four-finger line. The child showed later delayed mental development. Now, 8 years old, it cannot speak and has an intelligence quotient of less than 50. Investigation and counting of the chromosomes revealed only 146 in 88% of the cells, 47 in 6%, and less than 45 in 4%. Most unusual was the structure of the chromosomes, a picture which has never been seen before, namely the high variability of the arms of the chromosomes. They were unusually long in 25% of the cells, they showed breaks and deletion in 11%, and fusion of the arms in 27% of the cells. ABSTRACT AUTHORS: E. Fischer

L16 ANSWER 43 OF 45 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1964:33431 BIOSIS  
DOCUMENT NUMBER: PREV19644500033436; BA45:33436  
TITLE: The absence of antitumor effect of thalidomide on two grafted tumors.  
Original Title: Absence d'effet carcino-frenateur du thalidomide vis-a-vis de deux tumeurs greffees.  
AUTHOR(S): JURET, P.; AUBERT, C.  
CORPORATE SOURCE: Inst. Gustave Roussy., Villejuif., France  
SOURCE: COMPT REND SEANCES SOC BIOL [PARIS], (1963) Vol. 157, No. 2, pp. 246-249.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: Unavailable  
ENTRY DATE: Entered STN: May 2007  
Last Updated on STN: May 2007

AB Thalidomide does not inhibit either Guerin T8 epithelioma or Ehrlich ascites tumor. ABSTRACT AUTHORS: L. Amoriello

L16 ANSWER 44 OF 45 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1963:98840 BIOSIS  
DOCUMENT NUMBER: PREV19634400023766; BA44:23766  
TITLE: Effect of thalidomide on a variety of transplantable tumors.  
AUTHOR(S): DiPAOLO, JOSEPH A.  
CORPORATE SOURCE: Roswell Park Me. Inst., Buffalo, N. Y., USA  
SOURCE: CANCER CHEMOTHER REPTS, (1963) Vol. 29, pp. 99-102.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: Unavailable  
ENTRY DATE: Entered STN: May 2007  
Last Updated on STN: May 2007

L16 ANSWER 45 OF 45 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1963:90527 BIOSIS  
DOCUMENT NUMBER: PREV19634400015453; BA44:15453  
TITLE: Thalidomide: Influence on production of congenital abnormalities in mice and cancer chemotherapy.  
AUTHOR(S): Di PAOLO, JOSEPH  
CORPORATE SOURCE: Roswell Park Me. Inst., N. Y. Dept. Health, Buffalo, N. Y., USA



SOURCE: FED PROC, (1963) Vol. 22, No. 2 Pt. 1, pp. 666.  
Meeting Info.: 47th Annual meeting of the Federation of  
American Societies for Experimental Biology, 1963.  
DOCUMENT TYPE: Conference; (Meeting)  
FILE SEGMENT: BA  
LANGUAGE: Unavailable  
ENTRY DATE: Entered STN: May 2007  
Last Updated on STN: May 2007

=> d his

(FILE 'HOME' ENTERED AT 11:21:08 ON 02 MAR 2010)

FILE 'REGISTRY' ENTERED AT 11:21:22 ON 02 MAR 2010

L1 29 S THALIDOMIDE  
L2 1 S THALIDOMIDE/CN  
L3 3 S 50-35-1/RN OR 841-67-8/RN OR 2614-06-4/RN

FILE 'CAPLUS, 1MOBILITY, 2MOBILITY, CEABA-VTB, CHEMLIST, CHEMSAFE, CIN,  
CSNB, HEALSAFE, HSDB, INSPEC, ITRD, MSDS-CCOHS, MSDS-OHS, NAPRALERT,  
PASCAL, POLLUAB, PROMT, RTECS, SCISEARCH' ENTERED AT 11:24:36 ON 02 MAR  
2010

FILE 'CAPLUS' ENTERED AT 11:24:40 ON 02 MAR 2010

L4 3569 S L3  
L5 2230 S L4 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM? OR ?LEU  
L6 2 S L5 AND AD<19930301  
L7 2 DUP REM L6 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 11:27:01 ON 02 MAR 2010

FILE 'REGISTRY' ENTERED AT 11:27:11 ON 02 MAR 2010

SET SMARTSELECT ON  
L8 SEL L3 1- CHEM : 46 TERMS  
SET SMARTSELECT OFF

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 11:27:11 ON 02 MAR 2010

L9 24609 S L8  
L10 24609 S L9 OR L3  
L11 13424 S L10 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM? OR ?LE  
L12 235 S L11 AND PD<19930301  
L13 180 DUP REM L12 (55 DUPLICATES REMOVED)  
L14 152 S L13 NOT NECROSIS  
L15 53 S L14 AND THALIDOMIDE/TI  
L16 45 S L15 NOT GRAFT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE<br>ENTRY | TOTAL<br>SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST  | 123.98              | 269.29           |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE<br>ENTRY | TOTAL<br>SESSION |
|--|---------------------|------------------|
| CA SUBSCRIBER PRICE                        | 0.00                | -1.70            |

STN INTERNATIONAL LOGOFF AT 11:41:04 ON 02 MAR 2010